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General introduction and aims of the
studies
1. Definition of asthma
Asthma is a serious public health problem in countries throughout the world. It is one of
the most common chronic diseases worldwide (1). The current Global Initiative for
Asthma (GINA) guidelines provide the generally accepted definition for asthma:
Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular elements
play a role. The chronic inflammation causes an associated increase in airway hyperresponsiveness
that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particular
at night or in the early morning. These episodes are usually associated with widespread, but variable
airflow obstruction that is often reversible either spontaneously or with treatment (1).
For most patients with asthma this means that they are having a life-long chronic disease.
Asthma may affect children and adults of all ages, but in the majority of patients the first
symptoms start at young age. The fundamental causes of asthma are still not known.
Symptoms of breathlessness and wheezing occur often following exposure to allergens.
90% of the children with asthma are allergic to common airborne allergens such as
house dust mite (HDM), animals, fungi or pollen. Inhaler therapy with bronchodilators
may improve these symptoms, but in most patients continuous daily anti-inflammatory
therapy is needed to control symptoms. Although major improvements in asthma
medical treatment have taken place in the past decades, the disease may be severe and
sometimes fatal and can still not be cured (1).
2. Burden of asthma
In children, the prevalence of asthma symptoms varies widely between countries from
1.6% to even 36.8% (2). However, when an objective measurement as airway
hyperresponsiveness is also taken into account, the prevalence rates drop to 0-11.1% (1).
Although fewer data are available for adults, similar prevalence rates have been
described (3). The highest rates in Europe have been reported in the UK (2). 
Despite the large variation in asthma occurrence between countries, the reported
increase in prevalence of asthma during the eighties and nineties was very consistent
word-wide (4). In the UK, the prevalence of asthma at age 16 increased from 3.8% in
1974 to 6.5% in 1986. In the same study, the prevalence of eczema and hay fever doubled
in same period, suggesting that the increase in asthma was part of a general increase in
atopic disease (5). Although improved diagnosis may be an explanation for this, it
cannot explain the rise of asthma, since populations were studied with the same methods
on many occasions several years apart. The reasons for the differences in prevalence and
the recent increase are still poorly understood. There are now several reports suggesting
that the tide has turned. Asthma prevalence seems to be decreasing or at least no longer
increasing (6-10). A recent study in the Netherlands demonstrated that wheeze in Dutch
children has decreased from 13.4% in 1989 to 9.1% in 2001 (11). Interestingly, the study
reported that the use of asthma medication has increased. Possibly, better asthma control
may partly explain the concurrently decreasing trend in the prevalence of asthma. 
Even with improvements in treatment, patients may still die of asthma. Although
mortality data are unreliable in some countries, they may provide an indication of the
burden of asthma. Recently, standardised mortality rates (SMR) were published for
males (1.54 (1.10–2.09)) and for females (1.91 (1.44–2.49)) (12). Asthma morbidity and
mortality seems to increase with socioeconomic deprivation and ethnicity (13).
Asthma may have considerable impact on physical, emotional, social and economic
aspects of lives of patients (14). Despite the availability of effective therapies, asthma is
not optimally controlled in many patients (15). Sleep disturbance is reported in one
third of the children with asthma, whereas 60% report absence from school and activity
restrictions (16). Disability adjusted life years (DALYs) is a measure of the burden of
disease that assesses the years of healthy life lost due to disease or illness. The number of
DALYs lost due to asthma worldwide has been estimated to be about 15 million/year.
This makes asthma the 25th leading cause of DALYs lost worldwide in 2001 (17).
3. Risk factors for asthma
Asthma is a disease that may have multiple causes (1). The risk factors that might
contribute to the development of asthma can be divided in two main factors: host factors
and environmental exposure. These two factors may interact with each other both in the
induction and subsequent expression of the disease (18) (Figure 1).
3.1. Host factors
One of the most important risk factors for asthma is heritability. If the mother and/or
father have the disease, it is much more likely for the child to become allergic and
asthmatic (18). Although multiple genes have been demonstrated to be related to this
disorder, the asthma gene has not been identified yet and probably never will (19). The
ADAM33 gene on chromosome 20p12 is such a gene that has been linked with 
asthma (20). It has been associated with asthma and bronchial hyperresponsiveness (21).
Furthermore, polymorphisms of the ADAM33 are related to accelerated lung function
decline (22). Atopy is another important host factor that predisposes individuals to
develop this disease. It has been estimated that around one third of the asthma cases may
be attributable to atopy (23). Finally, having (asymptomatic) airway hyperresponsiveness
is an increased risk of becoming asthmatic (24).
3.2. Environmental exposures
In predisposed individuals, many environmental factors have been identified to increase
the risk of developing asthma. An important determinant for the risk on asthma is
exposure to house dust mite (25). An Australian study showed that in regions where







these children had significantly more wheeze (26). The relationship with exposure to
pets and asthma seems to be complex. Whereas dog ownership is not associated with
sensitisation, the presence of a cat in the home may affect the risk on asthma (27).
Exposure to cat dander may both increase as well as decrease the risk on 
sensitisation (27-30). It has been suggested that these conflicting results may be
explained by the fact that the dose-response relationship with cat allergen is bell-shaped
or that the timing of exposure (early or current pet ownership) is important or that high
levels of other allergens influence sensitisation (31). Furthermore, these results have also
been explained by the atopic status of the mother (32).
Respiratory syncytial virus (RSV) is a common cause of virus infection of the human
respiratory tract during the first two years of life (33). It has been suggested that RSV
infection may also predispose some children to the development of asthma (34). This is
based on many observations that children who wheeze with RSV-induced bronchiolitis
are more likely to develop into allergic asthmatics. In the Tucson Children’s Respiratory
study, one of the longest running respiratory cohort studies, RSV infection before the
age of 3 was associated with an increased risk of wheezing by the age of 6 and 11.
Remarkably, at the age of 13, RSV infection was no longer a risk factor for wheezing (35).
It is still unknown whether RSV is a causal factor for asthma or targets children who are
predisposed to asthma. 
Growing up on a farm may be protective against the development of atopy (36-39).
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Figure 1. Causes of asthma.
A multi causal pathway may lead to the development of asthma. Several factors have been related













However, exposures in the stables and farm in the first year of life seem to be crucial for
this protective effect (40). It may also explain the absence of this association in New
Zealand children (41). In contrast to central European farms where cattle are usually
kept in stables built near the farmhouse, in New Zealand animals on large farm holdings
stay outdoors throughout the year (42). The protective effect of living on a farm may
result from elevated exposure to endotoxin, which is an intrinsic part of the outer
membrane of gram-negative bacteria, since exposure to endotoxin is inversely related to
the occurrence of asthma (43).
Diet is known to have a large effect on risk of many different diseases. Also relations
between diet and the risk on asthma have been found. Consumption of fruit and
vegetables, in particularly vitamin C, has been associated with a decreased prevalence of
wheeze and asthma and may lead to a better lung function (44-46). In addition the
consumption of full cream milk and butter has been suggested to reduce the risk of
asthma (47).
4. Primary prevention of asthma
In view of the high prevalence of asthma and the fact that asthma cannot be cured,
primary prevention must be considered (48). Several randomised controlled trials
(RCTs) have attempted to reduce the risk on asthma. Studies investigating the effect of
house dust mite avoidance by mattress covers have shown disappointing results (49-51).
On the other hand, RCTs using multiple interventions have shown more effect. In the
Isle of Wight Prevention Study, the risk on asthma and allergic sensitization was
significantly reduced after an intervention on HDM avoidance combined with food
restrictions (52). Moreover, these results were still significant after 8 years of 
follow-up (53). Similar results have been obtained in the Canadian Asthma Primary
Prevention study after two and seven years of follow-up (54;55). The intervention in this
study included reduced exposure to indoor allergens, avoidance of environmental
tobacco smoke (ETS), encouragement of breast-feeding, and delayed introduction of
other foods during the first 12 months of life.
Interesting data for asthma prevention come from intervention studies using 
probiotics (56). The term probiotics is referring to living or inactivated organisms that
may exert beneficial effects on health when ingested. The most commonly used
probiotics are lactobacilli and bifidobacteria. The proposed rationale for using probiotics
against allergies and asthma is based on the relationship between the composition of
intestinal flora and the presence of allergies. The gut of infants born in poor areas of
developing countries, where allergy prevalence is low, is colonized earlier by lactobacilli
compared to the gut of infants born in developed countries (57). A prospective study
demonstrated that allergic children in Estonia and Sweden were less often colonized
with lactobacilli, as compared with non-allergic children (58). Finish and Swedish studies







atopy, suggesting a crucial role of the balance of intestinal bacteria for the maturation of
human immunity (59;60). The effect of probiotics on the development of asthma and
allergies has been tested in clinical studies. Kalliomäki and coworkers have shown that
Lactobacillus GG given prenatally to mothers and postnatally to their infants reduces the
frequency of atopic eczema in a randomized placebo-controlled trial (61). Furthermore,
the preventive effect of probiotics was persistent even at 4 years of age (62). Moreover,
even in infants, who manifested atopic eczema, probiotics may counteract the allergic
inflammation and thereby prevent further allergic disease (63). However, these studies
have not yet been able to demonstrate positive effects of probiotics on the development
of asthma.
Asthma is a multi-causal disease. As described above, several risk factors have been
associated with the development of asthma. Nevertheless, the disease is complex and up
to now can neither be cured nor be prevented. More understanding of the underlying
pathology might lead to better knowledge and thereby treatment of asthma.
5. Airway inflammation
Inflammation of the airways is the main pathological characteristic of asthma. The
inflammatory process can be separated into acute inflammation, chronic inflammation
and airway remodelling. These pathologic mechanisms may lead to specific and
overlapping clinical consequences for patients with asthma for example
bronchoconstriction (acute), exacerbations (chronic), and persistent airflow obstruction
(remodelling) (64). However, the link between these inflammatory features and clinical
expression of the disease is often weak (Figure 2).
5.1. Acute inflammation
After inhalation of allergens, the acute allergic reaction is initiated when an allergen
interacts with IgE that is bound to mast cells and basophils (65). These high-affinity IgE
receptor (FcRI) bearing cells release following activation preformed mediators,
membrane-derived lipids, cytokines and chemokines (66). The release of the pro-
inflammatory mediators such as histamine induces bronchoconstriction, mucus
secretion and vasodilatation (64). The narrowing of the airway lumen is further
increased via the induced microvascular leakage and edema (67). Antigen-presenting
cells such as dendritic cells are also crucial in the allergic reaction. Dendritic cells can
take up allergen and following the presentation of allergen to T cells, induce
proliferation of naïve T cells (68). In the “late-phase” reaction inflammatory cells, such
as eosinophils, CD4+ cells, basophils, neutrophils and macrophages are recruited and
activated (64). The activation of T cells leads to the release of T helper cell, type 2 (Th2)-
like cytokines that include IL-4, IL-5, IL-9, IL-13 (69).
The recruitment of cells into the airway wall is dependent on cytokines such as IL-5. IL-5
plays an important role in the mobilisation of eosinophils from the bone marrow (70).
12
The Koch postulates of causation might be useful to confirm the central role of IL-5 in
asthma. Indeed, elevated levels of IL-5 have been demonstrated in patients with asthma
and have been related with severity (71). Second, administration of IL-5 to animals and
humans has been associated with increased numbers of eosinophils, however its effects
on airway hyperresponsiveness are unclear (72;73). This has led to the following
questions: Would exogenous IL-5 lead to airway inflammation in asthma? Is the route 
of IL-5 production crucial to its effect on the airways in patients with asthma? (Chapter
2)
The fundamental importance of IgE in the pathogenesis of asthma has been clearly
identified (74). Burrows et al. were the first who showed a strong association between
serum IgE levels and self-reported asthma (75). Since then many epidemiological studies
have demonstrated the relationship between asthma and IgE (65;76). Furthermore, high
levels of circulating IgE have been shown to correlate with the risk of emergency room
admissions in patients with asthma (77). Like other antibodies, IgE has two identical
light and heavy chains. IgE has a very short half-life (<1 day) and is present in very low
concentration in the circulation (78). Cross-linking of IgE molecules on high-affinity IgE
receptors triggers the release of mediators by mast cells and basophils (79). Therefore,
these cells are highly sensitive to allergens even when the concentration of IgE is very
low. IgE production requires at least two distinct signals. The first signal is IL-4
(produced by T-cells, mast cells, basophils and eosinophils) and IL-13 (produced in
addition by natural killer cells). The second signal is delivered by the interaction of
CD40L on T cells with CD40 on B cells. The combination of these signals causes class
switching to IgE and B cell proliferation (80). Recently, the first monoclonal antibody
against IgE has been approved by Food and Drug Administration (FDA) in the US for
the treatment of patients with severe allergic asthma. This antibody recognizes IgE at the
same site as the high-affinity receptor for IgE (FcRI), but does not provoke histamine
release from IgE-sensitized mast cells (81).







Figure 2. Airway inflammation in asthma.
Examples of clinical features that may result from a typical inflammatory process. These features
are overlapping.
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allergens are the clear clinical features of this acute inflammatory process. This has led
to the following question: Is treatment with anti-IgE improving both the clinical features
and the inflammatory process in patients with asthma? (Chapter 7)
5.2. Chronic inflammation
All cells of the airways, including eosinophils, T cells, mast cells, macrophages, and
epithelial cells are involved in the chronic inflammation of asthma (82). Although
eosinophilic inflammation plays a central role in the disease, it is not specific to 
asthma (83). Moreover, a sub-type of non-eosinophilic asthma has been described (84). 
The number of bronchial eosinophils has been associated with the severity of 
asthma (85). Eosinophils are potentially harmful in asthma through the release of highly
toxic products (MBP, ECP, EDN and oxygen free radicals). The role of IL-5 in the
observed eosinophilia in asthma is important: IL-5 regulates the development and
differentiation of eosinophils, stimulates the release of eosinophils from the bone
marrow into the peripheral circulation and is involved in the activation and survival of
eosinophils (86). Interestingly, a study investigating the role of anti-IL-5 challenged the
central place of eosinophils in asthma. In this study, a monoclonal antibody against IL-5
reduced the levels of eosinophils in blood and sputum of patients with asthma. However,
it had no effect on early and late allergen response or airway hyperresponsiveness (87).
Therefore, it may be questionable whether eosinophils and airway hyperresponsiveness
are causally related in asthma.
T cells are likely to play a role in controlling the chronic inflammation through the
release of Th2-cytokines (88). The majority of T cells are CD4+ cells, whereas CD8+ cells
are less frequently identified, even during exacerbations of asthma (89). The frequency
of cytokine producing CD4+ and CD8+ cells is similar and is increased as compared with
normals (90;91). Interestingly, following glucocorticoid withdrawal, eosinophils are
elevated in all patients, whereas increases in airway T cells (both CD4+ and CD8+) were
found in only those who developed an exacerbation (92).
There is growing interest for the role of CD8+ T-cells in asthma. A cross-sectional
relationship between CD8+ T-cells and the outcome of asthma has been observed in
patients with fatal asthma (93). Furthermore, increased cytokine production of sputum
CD8+ T-cells has been shown to be related with disease severity in patients with 
asthma (93). Antigen specific CD8+ T-cells in the lungs demonstrate a high cytotoxic
activity and proliferate rapidly (94). These specific effector/memory T cells can be
rapidly activated by antigens, like allergens and viruses (95). In the host response to virus
infections, CD8+ T-cells may initiate eosinophil recruitment (95). Indeed, in mouse
models CD8+ T-cells appear to be essential for the influx of eosinophils into the lung and
the development of airway hyperresponsiveness during respiratory virus infections (96).
Furthermore, CD8+ T-cells are required for the development of airway
hyperresponsiveness following allergic sensitization (97) leading to increased
inflammation (98;99). Although an important role for CD8+ T-cells in asthma seems
likely, the association of CD8+ T-cells with asthma severity has only been demonstrated in
cross-sectional studies. This has led to the following question: Are CD8 cells related to
the outcome of asthma in a longitudinal study? (Chapter 5)
5.3. Airway wall remodelling
The structural changes in the airways of asthmatics, which are referred to as airway wall
remodelling, include thickening of the reticular basement membrane, increased airway
smooth muscle, epithelial shedding, altered deposition of extracellular matrix (ECM)
proteins. Since this process begins early in the development of asthma, remodelling may
occur in parallel or could even be required for the development of chronic
inflammation (100).
The basement membrane of the surface epithelium is composed of the basal lamina and
lamina reticularis. Thickening of the latter is an early characteristic feature of patients
with asthma (101). Epithelial reticular basement membrane thickening has been
demonstrated in children with asthma, although in symptomatic infants with reversible
airflow obstruction, it could not be found (102). In adults, following treatment with
inhaled steroids, the wall thickness was reduced, however it remained elevated as
compared to controls (103). Interestingly, a thicker airway wall as assessed by computed
tomography (CT) appears to be related to reduced airway hyperresponsiveness (104).
This suggests that the increased airway wall thickness, as observed in asthma, is
protective for airway hyperresponsiveness. In some (105;106), but not all studies (107),
the thickness of the sub-epithelial reticular layer was inversely associated with the level of
lung function in asthma. The clinical features of airway remodeling may be the
irreversible airway obstruction and decline in lung function, which is observed in
patients with asthma. However, until now there are no prospective studies, which have
shown a relationship between the thickness of the sub-epithelial reticular layer and lung
function decline in patients with asthma. This has led to the following question: Is the
thickness of the sub-epithelial reticular layer related to the outcome of asthma in a
prospective follow-up study? (Chapter 5)
6. Asthma management
The GINA guidelines propose a six-part asthma management program (1). The first part
involves patient education. In this way, patients will be able to achieve control of asthma
by adjusting medication according to a management plan.
In the second part, the assessment and monitoring of asthma severity is based on
symptoms and lung function (1). In order to quantify asthma symptoms, several
symptom scores and quality of life questionnaires have been developed (108;109). The
relationship between symptoms and other clinical measures is poor. Interestingly, a
factor analysis has shown that this is primarily due to the fact that asthma health status
has 4 distinct components: 1: asthma-specific quality of life, 2: airway calibre, 3: daytime







agonist use (110). Measurements of lung function are recommended and overcome the
problems of poor perception or under-reporting of symptoms by patients. Lung function
measurements, in particularly, the degree of reversibility to bronchodilators such as ß2-
agonists, give insight in airflow limitation, whereas measuring the variability of lung
function provides an assessment of airway hyperresponsiveness (1).
Peak expiratory flow (PEF) meters are useful for regular home monitoring of lung
function. PEF is mostly being recorded two times a day. The measurements can be
analysed and summarised in different ways: PEF-level (mean daily PEF, expressed as a
percentage of predicted or of personal best) and PEF-variability (amplitude as
percentage of mean value) (111) for the diagnosis of asthma, although its usage may be
limited due to poor sensitivity of the measurement (112-114). It has been suggested 
that PEF-variability may provide additional information when used in conjunction with
other clinical parameters for asthma patients, who are already on treatment (115).
Indeed, the effectiveness of treatment appeared to be associated with the level of 
PEF-variablity (116). However, PEF-variability may fail to detect an asthma 
exacerbation (117).Therefore, the minimum morning PEF over 1 week, expressed as a
percentage of recent best (Min%Max) has been suggested as an alternative, simpler
index of PEF-variability (118;119). The are few studies, which have shown contribution of
using PEF-variability to classify asthma control. This has led to the following question:
What is the value of including PEF-variability in addition to symptoms and ß2-agonist use,
in predicting the development of poor asthma control? (Chapter 6)
The third part of asthma management involves avoidance of exposure to risk factors. The
effectiveness of the reduction of allergen levels was shown in studies, which are
performed at high altitude where allergens levels are low (120;121). Although the use of
impermeable mattress cover seems to be ineffective, several other measures can be 
taken (122;123).
Pharmacological treatment (part four of the asthma management program) is needed in
most patients. Treatment of asthma aims to reverse and prevent symptoms and airflow
limitation (1). Medication can be divided into controllers and relievers. Controller
medications (inhaled glucocorticosteroids, long-acting ß2-agonists, and leukotriene
modifiers) have to be used daily for long-term to maintain control of persistent asthma.
At this moment, glucocorticosteroids are considered to be the most effective controller
medications (1). In RCTs, inhaled steroids have shown to improve airway
hyperresponsiveness and sputum eosinophils even in patients with mild asthma
(124;125). Furthermore, in studies using bronchial biopsies, reduction in the thickness
of the sub-epithelial reticular layer and a decrease in mast cells and eosinophils could be
demonstrated (126;127). Reliever medications (short-acting ß2-agonists and
anticholinergics) are needed to act quickly in reducing bronchoconstriction.
Despite optimal treatment, exacerbations of asthma may occur. Part five of the asthma
management plan concerns the managing of exacerbations. Exacerbations are often
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related to a viral infection (128). An increase in symptoms usually precedes the
worsening in lung function (129). Therefore, symptoms may be a sensitive marker for
the early onset of an exacerbation. The severity of an exacerbation is difficult to define.
Therapies include repetitive step-wise administration of short-acting ß2-agonists, systemic
glucocorticosteroids or even oxygen supplementation (1).
Finally, provision of regular follow-up care is needed in order to ensure that asthma
control is maintained. Even in patients who are in clinical remission of asthma airway
inflammation may still be present and treatment with inhaled steroids can be 
effective (130-132).
6.1. Limitations of asthma management
The assessment and monitoring of asthma control in the current guidelines is based on
symptoms and lung function. Although this approach leads to good control of asthma in
many patients, there is still room for improvement. As mentioned before, the burden of
asthma is high. Large surveys have shown that the level of asthma control falls short of
the goals for asthma management (15;133). Furthermore, asthma prognosis can be poor.
Long-term follow-up has shown that patients with asthma have an accelerated decline in
lung function (FEV1) as compared to controls (134-136). Moreover, in adult patients
with severe asthma, irreversible airway obstruction is common (137).
6.2. Improving asthma management
Several approaches are being undertaken to increase asthma control. First, asthma
management may be improved by optimizing the use of current available treatment.
Poor compliance to asthma medication has been repeatedly reported (138). Monitoring
medication adherence might improve compliance and thereby asthma control (139).
Interestingly, the internet appears to be a useful tool to reach this goal (140;141). It has
also been hypothesized that patients do not perceive the need for daily therapy and
therefore are not taking their medication. Based on this hypothesis, the efficacy of as-
needed corticosteroids has recently been investigated in mild intermittent asthma (142).
Second, new drugs for asthma are being developed. These therapies include anti-
inflammatory drugs (such as phosphodiesterase 4 (PDE4) inhibitors (143)) or “anti-
allergic” drugs directed against specific components of allergic inflammation (such as
omalizumab). Omalizumab, which is a humanized monoclonal antibody against IgE, is
the first monoclonal antibody drug developed for the treatment of moderate-to-severe
asthmatics to receive approval by the FDA in the US. The first clinical studies with
intravenous anti-IgE have shown that both early (EAR) and late (LAR) asthmatic
response to inhaled allergen are attenuated in patients with asthma (144;145). A recent
double-blind, placebo-controlled study confirmed the effectiveness of anti-IgE treatment
in inadequately controlled severe persistent asthma by showing a reduction in
exacerbation rate and emergency room visits and an improvement in quality of life and
morning peak expiratory flow rate (146). Although anti-IgE treatment has been shown







association with its clinical effect has not been made (147). This has led to the following
question: Can the clinical effect of anti-IgE be explained by a reduction in allergen-
induced airway inflammation? (Chapter 7).
Third, the measurement of non-invasive (more direct) markers of inflammation might
be beneficial for asthma management. The use of airway hyperresponsiveness (AHR),
inflammatory markers in sputum and exhaled nitric oxide (NO) in the management of
asthma will be discussed in the next paragraph.
7. Monitoring inflammation
Airway hyperresponsiveness can be defined as an increase in sensitivity to a wide variety
of airway narrowing stimuli (148). The degree of AHR is related to asthma severity and
airway inflammation (149;150). Furthermore, repeated measurements of AHR seem to
reflect the changes in asthma control in response to treatment (151). Interestingly,
asthma management based on reducing AHR on top of improving symptoms and lung
function leads to more effective asthma control (152). Compared with conventional
management, the AHR strategy resulted in fewer exacerbations, improved FEV1 and a
greater reduction in thickness of the sub-epithelial reticular layer.
The methods for sputum induction and processing have been recently 
standardized (153;154). The number of eosinophils in sputum is associated with asthma
severity (155). Furthermore, sputum eosinophils already increase before the onset of an
exacerbation (156). Following inhaled steroid treatment eosinophils in sputum
significantly decrease (157). Asthma management based on minimising eosinophils in
sputum has also been investigated. Patients in the “sputum management group” had
fewer exacerbations than the patients who received the current standard 
treatment (158). Other inflammatory markers in sputum for monitoring airway
inflammation in patients with asthma have been less thoroughly examined.
Microvascular leakage, which is also an important characteristic of airways inflammation
in asthma (67), has not often been measured to monitor inflammation in asthma. This
has led to the following question: Can induced sputum be applied to measure
microvascular leakage in patients with asthma? (Chapter 4).
Measurement of markers in exhaled air is non-invasive. In addition, exhaled NO has also
been proposed as a marker for disease severity in asthma (159;160). Patients with asthma
have increased levels of exhaled NO as compared to normals (161). Inhaled steroids
reduce the levels of exhaled NO in patients with asthma (162) in a dose-dependent 
way (163). Moreover, increases in exhaled NO are associated with a worsening in asthma
control (164). It was recently demonstrated that patients with asthma can be successfully
treated based on the levels of exhaled NO (165;166).
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One or more of the above-described non-invasive markers of inflammation will probably
be implemented in future asthma guidelines. However, a comparative analysis is required
before any of these markers can be recommended in the monitoring of asthma therapy.
This has led to the following question: What are the treatment-induced changes in airway
hyperresponsiveness, sputum eosinophils and exhaled NO in one comparative study?
(Chapter 3).
8. Aims of the studies
In summary, this thesis addresses three different aspects of airway inflammation in
asthma: role of inflammatory mediators in airway inflammation, monitoring of airway
inflammation and asthma management of airway inflammation. The above-mentioned
questions have been addressed in six studies relating to airway inflammation and asthma
management in asthma.
Role of inflammatory mediators in airway inflammation
Chapter 2. Would exogenous IL-5 lead to airway inflammation in asthma? Is the route of
IL-5 production crucial to its effect on the airways in patients with asthma? In this
chapter the effects of IL-5 administered intravenously or by inhalation to patients with
mild asthma was investigated on eosinophil counts in blood and in sputum, and on
airway hyperresponsiveness.
Monitoring of airway inflammation
Chapter 3. What are the corticosteroid-induced changes in airway hyperresponsiveness,
sputum eosinophils and exhaled NO in a comparative study? Twenty-five patients with
asthma were treated for 4 weeks with inhaled steroids or placebo. Before, during and
after treatment airway hyperresponsiveness, sputum eosinophils and exhaled NO were
measured.
Chapter 4. Can induced sputum be applied to measure microvascular leakage in patients
with asthma? This chapter examines the levels of albumin, fibrinogen, ceruloplasmin
and alpha-2-macroglobulin as markers of leakage in induced sputum before and after a
substance P challenge in patients with asthma. Inhaled NKA was used as a control
challenge in this randomised, placebo-controlled, crossover study.
Chapter 5. Are CD8+ T cells related to the outcome of asthma in a follow-up study? Is the
thickness of the sub-epithelial reticular layer related to the outcome of asthma in a
longitudinal study? In this chapter, we aimed to investigate the prognostic significance of
airway inflammation and remodelling on the decline in lung function in asthma. In 32
patients with asthma the relationship between bronchial eosinophils, CD8+ T cell, the
thickness of the sub-epithelial layer, and the annual decline in lung function after 71⁄2








Chapter 6. What is the value of including PEF-variability in addition to symptoms and ß2-
agonist use, in predicting the development of poor asthma control? In a prospective
study, we examined in 75 patients with asthma the value of including PEF-variability in
addition to symptoms and ß2-agonist use, in predicting the development of poor asthma
control. 
Chapter 7. Can the clinical effect of anti-IgE be explained by a reduction in allergen-
induced airway inflammation? In a randomized, double-blind, placebo-controlled study,
the effect of anti-IgE on allergen-induced airway inflammation in bronchial biopsies and
on the expression FcRI receptors and IgE+ cells was investigated in 25 patients with
asthma. Furthermore, the effect of anti-IgE treatment on peak flow, airway
hyperresponsiveness and sputum was determined.
Summary and conclusion
Chapter 8. A summary of the main results of the different studies is given in this chapter.
In addition, implications of these findings are discussed.
Chapter 9. In this chapter, a summary of this thesis is given in Dutch.
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Abstract
Background Interleukin-5 (IL-5) plays an important role in mobilisation of eosinophils
from the bone marrow and in their subsequent terminal differentiation. We investigated
whether IL-5 could induce pulmonary eosinophilia and bronchial hyperresponsiveness
(BHR) independently of these effects by examining the effects of inhaled and
intravenous administration of IL-5.
Methods Nine mild asthmatics received in random order inhaled (15µg) or intravenous
(2µg) IL-5 or placebo in a double blind, crossover study. Blood samples were taken prior
to and at 1/2, 1, 2, 3, 4, 5, 24 and 72 hours following IL-5 or placebo, and PC20
(methacholine) and eosinophil counts in induced sputum were determined.
Results Serum IL-5 was markedly increased 30 min after intravenous IL-5 (p=0.002), and
sputum IL-5 increased 4 and 24 hours after inhaled IL-5 (p<0.05). Serum eotaxin was
elevated 24 hours after intravenous but not inhaled IL-5 or placebo. Blood eosinophils
were markedly reduced from 0.5 – 2 hours following intravenous IL-5 (p<0.05), followed
by an increase at 3, 4, 5 and 72 hours (p<0.05). Sputum eosinophils rose significantly in
all three groups at 24 hours but there were no between-group differences. Bronchial
responsiveness (PC20) was not affected by IL-5.
Conclusion The effects of IL-5 appear to be mainly in the circulation, inducing
peripheral mobilisation of eosinophils to the circulation, without effect on eosinophil
mobilisation in the lungs and on bronchial responsiveness.
32
Introduction
Chronic asthma is characterised by an inflammation of the bronchi with the presence of
eosinophils and CD4+ T-helper cells (1,2). T-helper type 2 (Th2) cells are the
predominant source of the cytokine IL-5 and are elevated in the asthmatic airways (2).
IL-5 plays an important role in the mobilisation of eosinophils from the bone marrow,
and in the terminal differentiation and maintenance of mature eosinophils (3). IL-5
levels have been measured in the circulation of asthmatics (4), and rises during asthma
exacerbations (1). Additionally, increased IL-5 mRNA expression is seen in bronchial
mucosa and bronchoalveolar lavage CD4+ T cells in asthma (2,5), and IL-5 protein levels
increase following allergen challenge (6). A positive correlation between asthma severity
and IL-5 mRNA levels in bronchial biopsies has also been demonstrated (7).
In guinea pig and rodent models, airway administration of IL-5 induces an increase in
airway eosinophils without demonstrable change in bronchial responsivess (8,9). Airway
and blood eosinophilia has also been demonstrated in IL-5 transgenic mice, but without
bronchial hyperresponsiveness (10-12). IL-5 administration to the airways of asthmatic
subjects, however, has been associated with both peripheral blood eosinophilia, airway
eosinophilia and bronchial hyperresponsiveness (13;14). 
These conflicting observations suggest a complex co-operative role for IL-5 in the
accumulation of circulating and airway eosinophils and their possible subsequent
contribution to bronchial hyperresponsiveness. Since IL-5 also appears to have
important effects on the bone marrow (9,15,16), we questioned whether the route of IL-
5 production was crucial to its effects on the airways. We hypothesised that IL-5 confined
entirely to the lungs and airways would have little systemic effect on eosinophil
mobilisation, while IL-5 administered to the circulation might possess this primary effect.
Further, we sought to establish whether pulmonary or systemic IL5 could induce specific
pulmonary effects consistent with asthma. We therefore investigated the effects of IL-5
administered intravenously or by inhalation to patients with mild asthma on eosinophil
counts in blood and in sputum, and on airway hyperresponsiveness. 
Methods
Subjects
Nine non-smoking, atopic patients with mild persistent asthma (5 women, age range 
25-41 years) participated in this study (Table 1). All subjects had a history of episodic
chest tightness, and wheezing and symptoms were controlled by on-demand usage of
short-acting inhaled ß2-agonists alone. All subjects were free of respiratory tract infection
symptoms for at least 2 weeks prior to study commencement. Atopy was determined by
positive skin-prick responses (>3 mm) to extracts of 6 common aeroallergens
(Vivodiagnost, ALK, Benelux). Baseline forced expiratory volume in 1 second (FEV1)







methacholine), were determined by standardised technique (18). The protocol was
approved by the Ethics Committee of the Royal Brompton Hospital and all participants
gave written informed consent.
IL-5 administration
Recombinant human IL-5 (Genzyme, Boston, MA) was reconstituted in 0.9% NaCl (2ml)
and administered at a dose of 2 µg intravenously via a slow infusion in a forearm vein
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Table 1. Subject characteristics of mild asthma patients
Subject Sex Age FEV1 PC20 Sputum
(years) (% pred) (mg/ml) Eosinophils (%)
1 M 35 94 0.15 2.3
2 F 26 85.6 0.19 0.5
3 F 26 79 0.37 6.3
4 F 27 95 0.42 1.1
5 F 36 97 1.44 1.0
6 F 25 117 2.79 0.0
7 M 29 106 3.73 5.9
8 M 28 97 6.68 0.5
9 M 41 85 8.00 0.2
30.3 ± 5.6* 95.1 ± 3.8* 1.15 ± 2.21# 1.00 (0-6.3)†
* mean-SEM; # geometric mean-SD in doubling doses; † median (range).
Figure 1. Study design. Subjects were treated in random order with inhaled IL-5, intravenous IL-5
or placebo, in a cross-over design at 2 week intervals. Specimen sampling was performed at time-
points noted.
IL5 = administration of inhaled(15 µg), intravenous (2 µg) IL-5 or placebo
B = blood sample
P = PC20 methacholine
S = sputum induction
over a period of 5 mins. This intravenous dose was calculated according to the levels of
circulating IL-5 measured in circulating blood of patients with asthma during an
exacerbation (1). IL-5 (15µg) was inhaled over 5 minutes via a nebulizer (MECIC-AID,
Pagham, Sussex, UK) from a mouthpiece using a one-way exhaust valve (LC Plus, PARI,
Surrey, UK). To ensure complete inhalation of the IL-5, the chamber was then refilled
with 2ml 0.9% NaCl and the nebulisation repeated.
Lung function and methacholine challenge
Baseline FEV1 was recorded from the best of three attempts using a dry wedge
spirometer (Vitalogragh, Buckingham, UK) (17). Spirometry was performed prior to
and hourly after the administration of IL-5 or placebo until the start of methacholine
challenge at 4h. Methacholine challenges were performed according to a standardised
methodology (18). After a nebulized saline challenge, doubling doses of methacholine
(0.06-32 mg/ml) were administered via a dosimeter (Mefar, Bovezzo, Italy) with an
output of 100µl. A total of five inhalations of each concentration was administered
(inhalation time one sec and breath-holding time six sec). FEV1 was measured 2 and 3
min after each dose. The test was discontinued if FEV1 as compared with the control
inhalation (0.9% NaCl) decreased by 20% or more. The PC20 was calculated by log-linear
interpolation of the last two data-points.
Peripheral blood eosinophil counts
Peripheral blood eosinophils were identified by the combination of peroxidase staining
and side scatter and enumerated using the automated Advia 120 Hematology System
(Bayer, Newbury, Berks, UK).
Sputum induction
All subjects received 200µg salbutamol following the methacholine challenge. After
recovery, sputum was induced according to a previously-described method (19).
Hypertonic saline aerosols (NaCl 3.5%) were nebulised at room temperature via an
ultrasonic nebuliser (DeVilbiss Ultraneb 2000) at maximum output. Subjects inhaled the
aerosols during 3 x 5-minute intervals. Between each interval, or as soon as the subjects
started coughing, they were instructed to wash their mouth and blow their nose in order
to minimise salivary contamination. The induced sputum was collected into a 50-ml tube,
kept at 4°C and processed within two hours.
Sputum processing
The whole sputum sample was diluted with 2 ml Hank’s balanced salt solution (HBSS)
containing 0.25% dithiotreitol (DTT; Sigma Chemicals, Poole, UK). The sample was
gently mixed at room temperature, the volume determined and the sample further
diluted with HBSS to 10 ml. The sample was centrifuged (350g, 10 min), supernatant was
removed and the cell pellet resuspended in 1 ml HBSS. Total cell counts were
determined on a haemacytometer slide. Cytospin slides were prepared (600 rpm, 6 min;
Shandon, Runcorn, UK) and stained with May-Grunwald-Giemsa. Differential cell counts







two slides. To correct for the variable salivary contamination, differential cell counts were
expressed as a percentage of 300 nucleated cells, excluding squamous epithelial cells. An
adequate sample was defined if there was < 80% squamous cell contamination.
Supernatants were stored at –80oC.
IL-5 and eotaxin assays
Serum IL-5 and eotaxin and sputum IL-5 levels were measured by ELISA according to
the manufacturer’s instructions (Pharmingen, Cambridge, UK). Briefly, purified rat anti-
human monoclonal antibodies were incubated at 2 µg/ml in coating solution (0.1M
NaHCO3 (BDH) pH 8.2 at 4 °C) overnight. Plates were washed then blocked with 10%
FCS for 2h at room temperature. Sample supernatants were added to each plate in
duplicate. Cytokine standards (R&D Systems, Abingdon, Oxon, UK) were diluted in 10%
(v/v) FCS/PBS/Tween and added in duplicate. Plates were then incubated at 4o C
overnight. Biotinylated rat anti-human antibody (R&D) was added and incubated at
room temperature for 45 mins then washed before the addition of avidin-peroxidase.
Plates were incubated at room temperature for 30mins before washing with PBS/Tween
and (ABTS - Sigma) substrate. Plates developed for approximately 10 minutes before
measurement on a plate reader (Anthos Labtec, Austria) at 405nm. The detection limit
of this assay was 35 pg/ml. 
Data analysis
PC20 was log-transformed before statistical analysis and reported as geometric mean 
(± SD). IL-5 levels and blood and sputum eosinophils were not normally distributed and
were therefore log-transformed prior to analysis and reported as median (range), for
eosinophils, and geometric mean (± SD), for IL-5 levels. For between group analyses,
analysis of variance (ANOVA) for repeated measures was applied. Within group changes
in PC20, sputum and blood eosinophils, serum and sputum supernatant IL-5 were
analyzed using the Student’s paired t-test. Mean differences between treatments with
95% confidence intervals for these effect estimates are presented for serum IL-5 and
blood eosinophil counts. All statistical analyses were performed using the SPSS program.
P-values < 0.05 were considered as statistically significant.
Results
Serum and sputum IL-5 levels
Serum IL-5 levels was rapidly cleared from the circulation and returned to baseline levels
between 1 and 72 hours. Serum IL-5 concentrations in atopic asthmatics increased
significantly 0.5 hours following intravenous IL-5 administration (387.4 ± 162.1 pg/ml),
compared with baseline (14.0 ± 12.8 pg/ml, p=0.002), with rapid clearance, returning to
baseline levels between 1 and 72 hours (Figure 2). The levels of serum IL-5 at 1, 2, 3, 4
and 5 hours after intravenous IL-5 were 16.8 ± 5.9, 14.2 ± 8.4, 5.7 ± 3.5, 8.1 ± 3.9, and 3.7
± 2.0 pg/ml respectively, indicating that by one hour the levels had returned towards
baseline values. In order to determine whether there was any difference in the kinetics 
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of clearance of IL-5 between asthmatic and non-asthmatic volunteers, we also studied 
3 non-asthmatic non-atopic volunteers. After 2 µg intravenous injection, serum IL-5
measured in non-asthmatic subjects was 3.6 ± 2.5 pg/ml at baseline and increased to 54.2
± 24.6 pg/ml 0.5 hours following intravenous IL-5 (mean difference –60.53, 95% CI
–107.7 - -13.3, p<0.05; Figure 2). These data indicate that there is no difference in the
clearance in IL-5 between normal and asthmatic volunteers, although the asthmatics had
higher levels of baseline serum IL-5 than non-asthmatics. There was a trend to elevation
of serum IL-5 half an hour following inhaled IL-5 administration (18.18 ± 12.4 pg/ml to
51.14 ± 100.56 pg/ml) in the asthmatic subjects, but serum IL-5 was not affected by
placebo. There was a significant increase in the IL-5 concentration measured in sputum
supernatant from baseline at 4 and 24 hours following inhaled IL-5 (baseline: 49.0 ±










A. Mean IL-5 serum levels. Serum IL-5 levels rose markedly following intravenous IL-5 but were not
significantly elevated by inhaled IL-5 or placebo in patients with mild asthma. In addition, in
normal volunteers, the administration of intravenous IL-5 led to a peak of serum IL-5 levels at
0.5 hr similar to that in asthma patients.
B. Mean IL-5 levels in sputum supernatants. Sputum IL-5 levels rose 4 hours following 
inhaled IL-5 and remained elevated at 24 hours but, were not affected by intravenous IL-5 or
placebo.
respectively), but no changes in sputum supernatant IL-5 following placebo or
intravenous IL-5.
Serum eotaxin
Serum eotaxin levels were 207.5 ± 80.2 ng/ml at baseline, 248.1 ± 93.6 at 0.5 hours, 
232.5 ± 101 at 4 hours and 301.4 ± 113.6 at 24 hours following intravenous IL-5. There
was a trend to increase in serum eotaxin following intravenous IL-5 with a 43.0 ± 23.3%
increase at 24 hours compared to baseline (Figure 3). Comparative eotaxin levels
following inhaled IL-5 was 12.0 ± 23.8 and after placebo 1.5 ± 6.8. No correlation was
observed between peak IL-5 levels (0.5 hours) and eotaxin levels at 0.5 or 24 hours
following IL-5, nor was there correlation between eotaxin levels and peripheral blood
lymphocyte or eosinophil numbers.
Effect of IL-5 on peripheral blood cells
Blood eosinophils were reduced 30 minutes (mean difference 0.15, 95% CI 0.05 – 0.26,
p<0.01) and 2 hours (0.13, 0.02 – 0.24, p<0.05) following the administration of
intravenous IL-5 compared with baseline (Figure 4). The decrease in eosinophils 0.5
hours after intravenous administration was significantly different from changes following
inhaled IL-5 and placebo (p<0.03). The increase in blood eosinophil counts observed at
3, 4, 5 and 72 hours was not statistically significant.
Additionally, peripheral blood lymphocytes were significantly increased from baseline at
4 (p<0.01, mean difference –0.54, 95% CI -0.97 - -0.11) and 5 hours (p<0.001, -0.59, -1.02
- -0.16) following intravenous but not inhaled IL-5 or placebo.
Effect of IL-5 on sputum eosinophils
The sputum eosinophil counts were 1.0% (0-6.3) (median (range)) at baseline.
Following inhaled IL-5, sputum eosinophils increased to 5.0% (median) at 24 hours
(p=0.02), and persisted at 72 hrs (4.6%, p=0.02). However, similar increases were
observed after intravenous IL-5 and after placebo treatment (median at 24 hours: 3.6%
and 3.7%, respectively, p<0.01). There were no significant differences in sputum
eosinophils between the treatment groups (Figure 5).
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Figure 3. Serum eotaxin. There
was a non-significant trend to
increase in serum eotaxin levels
24 hours following intravenous IL-






















Effect of IL-5 on lung function and bronchial responsiveness
Baseline FEV1 was 95.1 ± 3.8% predicted, and PC20 was 1.15 ± 2.21 mg/ml. No significant
changes were observed in FEV1 or PC20 during the 3 different study periods (Figure 6).
There were no significant correlations between sputum IL-5 levels and change in PC20,
nor between eosinophils in blood or sputum with levels of IL-5 measured in sputum or in
serum.
Discussion
In this study, we report the first observations on the comparative effects of inhaled and
intravenous IL-5 in mild asthma. We observed marked elevations of IL-5 levels in the
serum but not in the sputum when administered intravenously, and the other way round
when given by inhalation. Thus, inhaled IL-5 appeared confined to the lung and
intravenous IL-5 to the blood compartment. Intravenous IL-5 induced a rapid decline
and subsequent non-significant rise in blood eosinophils which was not associated with
airway eosinophilia or bronchial hyperresponsiveness. Sputum eosinophils were indeed
slightly increased after intravenous and inhaled IL-5 but were also observed following








Left panel: Time course of blood eosinophil counts after placebo or inhaled IL-5 or intravenous IL-
5. Intravenous IL-5 induced a rapid fall in circulating eosinophil numbers (p<0.05), not seen
following inhaled IL-5 or placebo. There was a prolonged but non-significant elevation of
eosinophils at 3, 4, 5 and 72 hours after intravenous IL-5. Data shown as mean ± SEM.
Right panel: Time course of changes in blood neutrophil, lymphocyte and eosinophil counts after
intravenous IL-5. Data shown as mean ± SEM.
Figure 4A Figure 4B
effect as reflected by blood eosinophils or serum eotaxin levels and did not affect
bronchial responsiveness. A trend to elevated serum eotaxin levels was observed 24 hours
following intravenous IL-5. The cellular source of this increase in eotaxin levels could
have been the vascular endothelial cells, or circulating eosinophil and T-cells. Systemic
IL-5 is a potent stimulus to eosinophil mobilisation to the circulation, albeit not in itself
sufficient to specifically induce lung eosinophilia (as measured in induced sputum) or
airway hyperresponsiveness.
We observed significant, sequential and converse effects on peripheral blood eosinophils
following intravenous IL-5. Between 0.5 and 2 hours, eosinophils were markedly
reduced, and this effect has not been previously reported in animals or humans. At later
time-points (4-72 hours) there was significant elevation of blood eosinophil counts. We
speculate that these effects result from rapid vascular margination followed by, either
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Figure 5. Mean sputtum eosinophil counts. Sputum eosinophils were elevated four hours from
baseline in each of the treatment groups, but no between-group differences occurred at any of the
time points measured.
Figure 6. Mean log PC20 to methacholine. Bronchial responsiveness did not change significantly
from baseline after inhaled IL-5, intravenous IL-5 or placebo.
demargination or replenishment of the circulating eosinophil pool from bone marrow,
and other extra-medullary leukocyte reservoirs. A rapidly-induced but short-lived
peripheral eosinophilia has been observed previously following intravenous IL-5 in
animals (20;21), while a prolonged peripheral blood eosinophilia occurred after inhaled
IL-5 in human asthmatics (13).
That IL-5 did not specifically affect sputum eosinophils levels contradicts a previous study
of IL-5 inhalation in mild asthmatics (14). We observed minor but significant increases
in sputum eosinophil numbers in all groups. These changes are unlikely to be explained
by methacholine challenge (22) or repeated sputum induction (23). Our findings are,
however, consistent with previous studies in rodents. Wang et al (1998) (24)
demonstrated that circulating IL-5 is essential for the development of airway
eosinophilia, whereas local lung IL-5 production did not lead to eosinophil recruitment
to the lungs. Similarly, Mould et al (2000) (11) observed a doubling of eosinophil counts
in bronchoalveolar lavage fluid following the administration of intrapulmonary and
intravenous IL-5 compared to intrapulmonary IL-5 administration alone in mice. Lee
and coworkers (1997) created an IL-5 transgenic mouse expressing IL-5 in airway
epithelium which developed baseline bronchial hyperresponsiveness and BAL
eosinophilia; however, in this model IL-5 was expressed at unusually high levels in serum
with concomitant prominent peripheral eosinophilia (12)..
We saw no effect of IL-5 on bronchial responsiveness. Consistent findings are provided in
human studies in which monoclonal anti-IL-5 blocking antibodies substantially reduced
allergen-induced blood and sputum eosinophilia but had no effect on the late phase
response and bronchial hyperresponsiveness to allergen challenge (25). These findings
have been consistently confirmed in animal models (26;27). The contribution of IL-5 to
bronchial hyperresponsiveness is contentious and in asthma models, difficult to
dissociate from effects induced by mediators other than IL-5 (28-31). Consistently
however, IL-5 transgenic mice have prominent airway eosinophilia but have acetylcholine
responses similar to wild type mice (32). These studies collectively suggest a close
association between IL-5 and both circulating and bronchial eosinophil numbers but a
dissociation between pulmonary IL-5 and bronchial responsiveness in both animals and
humans (25; 31-33). 
Our observations are substantially different from those of Shi et al (14) in terms of
sputum eosinophilia and bronchial responsiveness induced by IL-5, despite using similar
amounts of inhaled IL-5 obtained from a similar source, and comparable cohorts of
asthmatics in terms of severity and baseline sputum eosinophilia. These studies were
performed in ethnically different populations raising the possibility that there may be
racial susceptibility to the effects of IL-5. Another possibility is that the high level of
endemic parasitic colonization in China (34-36) may induce an expanded population of
activated tissue eosinophils(35-37), that are primed to respond more to IL-5. Sputum
ECP levels in the mild asthmatics studied by Shi et al were, however, 2-log fold higher







Collins et al 1995 (9) reported that in contrast with intravenous administration, local IL-
5 did not induce tissue accumulation of eosinophils (9). This indicates that local IL-5 has
little chemoattractant activity, whereas intravenous IL-5 has a rapid enhancing effect on
eosinophil accumulation, by stimulating the release of a rapidly mobilizable pool of bone
marrow eosinophils. Furthermore, although IL-5 is necessary, other signals from
activated T lymphocytes may also be required to induce accumulation of eosinophils in
the airways (20;39;40). Eotaxin, an eosinophil selective chemokine, augments the
accumulation of eosinophils by IL-5 in a synergistic fashion. This implies that IL-5 and
eotaxin act co-operatively to promote the recruitment of eosinophils into the tissue
(9;20) Our data indicates that IL-5 when administered on its own to the airways by
aerosol is not capable of inducing eosinophilic inflammation and bronchial
hyperresponsiveness in mild asthmatic subjects. However, changes in circulating
eosinophil numbers were observed with intravenous administration of IL-5, indicating
potential systemic effects on the bone marrow. Thus, IL-5 may have systemic rather than
pulmonary effects in asthma.
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Abstract
Background Airway hyperresponsiveness, induced sputum eosinophils and exhaled nitric
oxide (NO) have all been proposed as non-invasive markers to monitor airway
inflammation in patients with asthma. The aim of the present study was to compare the
changes in each of these markers as obtained by inhaled glucocorticoids in one single
study.
Methods In a randomized, double-blind, placebo-controlled, parallel study, 25 patients
with mild asthma (19-34 yr, FEV1>75% predicted, PC20<4 mg/ml) inhaled fluticasone
propionate (500 µg, bid) for 4 weeks. PC20 to histamine, sputum eosinophils and exhaled
NO were determined at weeks 0, 2, 4, and after 2 weeks wash-out (week 6). Sputum was
induced by inhalation of hypertonic (4.5%) saline, and eosinophils counts were
expressed as % non-squamous cells. Exhaled NO (ppb) was measured by
chemiluminescense.
Results Within the steroid group, there was a significant increase in PC20, decrease in
sputum eosinophils and decrease in exhaled NO as compared with baseline at weeks 2
and 4 of treatment (p<0.01). Subsequently, each of these variables showed significant
worsening during two weeks run-out as compared with week 4 (p<0.01). These changes
were significantly different from those in the placebo group (p<0.05), except for the
changes in sputum eosinophils from baseline to week 2 and from week 4 to 2 weeks wash-
out. There were no significant correlations between the changes in the three markers in
either group at any time.
Conclusion We conclude that 4 weeks of treatment with inhaled steroids leads to
improvements in airway hyperresponsiveness to histamine, eosinophil counts in induced
sputum, and exhaled nitric oxide levels. Our results suggest that these markers may




Asthma is an inflammatory disease of the airways, associated with airway
hyperresponsiveness to various bronchoconstrictor stimuli, such as histamine (1). The
accompanying inflammation is characterized by the presence of inflammatory cells, such
as T-lymphocytes, neutrophils and eosinophils, and their cytokines in the airway mucosa
as demonstrated in bronchial biopsy specimens (2,3). The current treatment of
asthmatic patients is based on reducing or preventing airway inflammation as guided by
lung function and symptoms (1,4). To monitor airway inflammation more closely,
measurement of non-invasive and sensitive markers of inflammation, such as airway
hyperresponsiveness (5), sputum eosinophils (6) or exhaled NO (7) during treatment
follow-up in patients with asthma has recently been suggested.
To date, inhaled glucocorticoids are the most effective treatment of asthma not only
reducing symptoms and airway hyperresponsiveness (8), but also leading to an
improvement of airway inflammation (9). However, there is recent evidence that therapy
according to the present international guidelines provides only partial suppression of
airway inflammation, as shown by persisting eosinophilic inflammation in the bronchial
(sub)mucosa after long-term inhaled steroid treatment (5).
Among the non-invasive techniques, hypertonic saline-induced sputum has been shown
to be a reliable method to measure eosinophilic airways inflammation (6,10,11). The
number of eosinophils in sputum is associated with asthma severity (10) and decreases
following inhaled steroid treatment (12). In addition, nitric oxide levels in exhaled air
have also been proposed as marker for disease severity in asthma (7,13). Indeed, inhaled
glucocorticoids decrease the levels of exhaled NO in patients with asthma (14), in a
dose-dependent way (15).
Although the effects of inhaled steroids on sputum eosinophils and exhaled NO have been
well established, comparative analysis is required before any of these markers can be
recommended in the monitoring of asthma therapy. In the present study we investigated
treatment-induced changes in airway hyperresponsiveness, sputum eosinophils and
exhaled NO in asthma. To that end, we performed histamine challenge, induced sputum
and exhaled NO measurements before, during and after 4 weeks treatment with
fluticasone propionate or placebo in steroid-naive patients with asthma.
Methods
Subjects
Twenty-five non-smoking, atopic patients (9 female and 16 male, 19-34 years) with mild
persistent asthma (1) voluntered to participate in this study (Table 1). Symptoms of
episodic chest tightness and wheezing were treated by on-demand usage of inhaled







weeks before the study all subjects were free of symptoms of respiratory tract infection.
Atopy was indicated by a positive skin prick test (> 3 mm wheal) to one or more of 10
common airborne allergen extracts (Vivodi–agnost, ALK, The Netherlands). The forced
expiratory volume in one second (FEV1) was greater than 75 % of the predicted value
(16), and all subjects were hyperresponsive to inhaled histamine (PC20 < 4 mg/ml) (17).
The study was approved by the Medical Ethics Committee of the Leiden University
Medical Center, and a signed informed consent was obtained from all volunteers.
Design
The study had a randomized, double-blind, placebo-controlled parallel design. During
screening, the selection criteria were checked for all subjects. Before entering the
treatment period baseline values of PC20 histamine and percentage eosinophils in
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Table 1. Characteristics of the subjects
Subject Sex Age FEV1 PC20 EO NO
No. (yr) (% pred) (mg/ml) (%) (ppb)
Steroid
1 M 24 77 0.07 1.4 5.85
2 M 24 104 0.37 3.8 10.75
3 M 21 104 0.39 5.8 11.81
4 F 23 88 0.55 7.6 5.28
5 F 20 83 0.71 4.0 3.42
6 M 24 103 0.72 0.0 8.24
7 M 23 94 1.29 3.6 10.21
8 F 24 101 1.81 0.2 7.25
9 F 21 99 2.05 NA 2.17
10 M 28 104 2.54 3.4 2.15
11 F 21 98 3.14 1.4 3.92
12 M 27 99 3.14 0.2 4.62
23.3 96.2 0.91 3.40 5.57
(2.4)¶ (9.0)¶ (1.62)* (0.0,7.6)§ (2.15,11.81)§
Placebo
13 M 24 82 0.11 21.2 13.41
14 F 21 108 0.11 0.0 6.57
15 M 29 111 0.14 24.6 12.05
16 M 34 83 0.30 0.0 4.17
17 M 21 98 0.46 1.6 13.40
18 M 24 80 0.54 NA 14.08
19 M 25 86 0.73 0.0 3.26
20 M 24 98 0.77 1.8 4.22
21 F 24 106 0.89 3.2 2.48
22 M 28 90 1.00 1.2 3.36
23 F 28 106 1.20 NA 5.05
24 F 25 98 1.51 0.0 5.82
25 M 19 97 1.70 0.4 9.26
25.1 95.6 0.52 1.20 5.82
(3.9)¶ (10.6)¶ (1.38)* (0.0,24.6)§ (2.48,14.08)§
¶ = mean (SD), * = geometric mean (SD) in DD, § = median (range), NA = not applicable
induced sputum were determined. These two measurements were carried out on two
separate days, with a 2-4 days interval. Prior to histamine challenge and sputum
induction, baseline values of FEV1 and exhaled NO were recorded. This sequence of
measurements was used at all time points of the study. Directly following the second
baseline visit, the subjects were treated with inhaled fluticasone propionate (500 µg bid)
or placebo for a period of four weeks. The measurement of PC20 histamine, sputum
eosinophils, FEV1 and exhaled NO were repeated during the treatment period (at weeks
2 and 4) and during wash-out at two weeks after the treatment period.
Histamine challenge
Histamine challenges were performed according to a standardized methodology (17).
Histamine-di-phosphate (Sigma Chemicals, St.Louis, MO, USA) in PBS was stored at 4°C
and administered at room temperature. Doubling concentrations between 0.06 and 16
mg/ml were used. The aerosols were generated by a DeVilbiss 646 nebulizer (output:
0.13 ml/min), connected to an in- and expiratory valve box with an expiratory aerosol
filter (Pall Ultipor BB50T). Each dose was inhaled through the mouth by tidal breathing
for 2 minutes at 5-minute intervals, with the nose clipped (17). The airway responses to
the inhaled aerosols were measured using FEV1, recorded by a dry rolling-seal
spirometer (Morgan Spiroflow, Morgan UK) and monitored on-line by a personal
computer with a special soft-ware program. Before each test FEV1 was measured in
triplicate, for calculation of mean baseline levels (17). The airway response was recorded
at 30 and 90 seconds after each dose. After each inhalation, the lowest, technically
satisfactory FEV1 value was applied in the analysis to calculate the percentage fall in FEV1
from baseline. The test was discontinued if FEV1 was decreased by 20% or more. The
provocative concentration causing 20 % fall in FEV1 (PC20) was calculated by log-linear
interpolation of the final two data points.
Sputum induction
Sputum was induced and processed by the so called full-sample method (18) according
to a protocol that has been validated in our laboratory (6). Hypertonic saline aerosols
(NaCl 4.5%) were generated at room temperature by a DeVilbiss Ultraneb 2000
ultrasonic nebulizer with a calibrated particle size (MMAD 4.5 mm) at maximal output
(2.5 ml/min). The aerosols were administered to the subjects through a 100 cm long
tube with an internal diameter of 22 cm, and inhaled via the mouth through a two-way
valve (No. 2700; Hans-Rudolph, Kansas City, MO, USA), with the nose clipped. Before
inhalation of the aerosols, baseline FEV1 was recorded and, for safety reasons, 400 µg
salbutamol was administered through a metered dose inhaler (Volumatic). Subsequently,
the subjects inhaled hypertonic saline aerosols during 2 x 5 min and 1 x 10 min intervals.
After each inhalation, or as soon as the subjects experienced cough, they were asked to
blow their nose, to rinse their mouth and throat with water, and to expectorate sputum
into a clean plastic container by coughing. After testing, FEV1 was measured, and







Sputum processing and cell differential counts
The volume of the induced sputum samples was determined and mixed with an equal
volume of 0.1% sputolysin (dithiotreitol, Calbiochem, USA) (6). To ensure complete
homogenization, the samples were placed in a shaking water bath at 37 °C for 15
minutes, once interrupted by gently mixing the sample. The homogenized sputum was
centrifuged (350 x g) for 10 minutes at room temperature. The cell pellet was
resuspended in PBS to a final volume of 2-5 ml, followed by filtration through a gauze
(pore-size approximately 1 mm) to remove clumbs. Total cell counts were performed in
a haemacytometer (Tamson, Zoetermeer, The Netherlands). Subsequently the sample
was diluted with PBS to a final concentration of ±0.3 x 106 cells/ml which was used for
preparation of the cytocentrifuge slides (1500 rpm, 3 minutes, 50 ml/slide) (Shandon 3,
Life Sciences International, Veldhoven, The Netherlands). Differential cells counts of
eosinophils, neutrophils, lymphocytes, macrophages, epithelial and squamous cells were
performed on Diff-Quik stained, cytospins by a qualified cytopathologist. To correct for
the variable salivary contamination, differential leukocyte and cylindric epithelial cell
counts were expressed as a percentage of 250 nucleated cells excluding squamous cells.
For each sample, differential cell counts were performed twice by the same observer, and
the mean data were used in the analysis. A sputum sample was considered adequate
when the percentage squamous cells was less than 80%. The reproducibility of the
sputum cell counts as obtained by this method has been shown to be satisfactory (6). To
ensure a blind analysis of the sputum samples, all cytocentrifuge slides were coded
before analysis by an investigator who was not involved in the counting.
Exhaled NO
Exhaled NO levels were measured by a chemiluminescense analyzer (Sievers NOA 270B)
according to a standardized procedure (7), which has previously been applied by our lab
(19). The subjects were connected to a closed system to avoid contamination of the
measurements with ambient NO. Pressured air with low NO concentration (< 1ppb) was
administered through a 150 L reservoir connected to the inspiratory side of a Hans-
Rudolph three-way valve. The subjects performed a slow vital capacity manoeuvre with a
constant expiratory flow of 10L/min against an expiratory resistance of 3-4cm H2O.
Expiratory NO concentration was sampled continuously from the centre of the
mouthpiece at a sample flow of 440 ml/min, and the average concentration (in parts per
billion; ppb) was determined for a period of 10 seconds (7). Baseline values of exhaled
NO were obtained from the mean values of the two NO measurements recorded before
histamine challenge and sputum induction, because the reproducibility was good
(intraclass correlation coefficient, R i > 0.92).
Analysis of data
PC20 was log-transformed before statistical analysis, and expressed as geometric mean
(SD) in doubling dose. To test for differences between and within the treatment groups
in general, multivariate analysis of variance (MANOVA) was applied for FEV1 and log
PC20, whilst Kruskal-Wallis test was used for sputum eosinophils and exhaled NO. The
changes in PC20 (expressed in doubling doses: DD) within each treatment group were
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analysed using Student’s paired t-test, whilst the changes in PC20 between both groups
were tested using Student’s unpaired t-test. Since exhaled NO levels and sputum
eosinophils were not normally distributed, these markers were analysed non-
parametrically. The Wilcoxon signed-rank test was used to test for the differences within
each treatment group. Furthermore, the Mann-Whitney signed-rank test was applied to
test for the differences between the groups in changes in sputum eosinophils and
exhaled NO at all time-points as compared with baseline. Finally, Spearman rank
correlation analysis was used to examine the relationship between the changes in PC20,
sputum eosinophils and exhaled NO. Results were considered significant if p value <
0.05. All statistical analyses were performed using SPSS.
Results
Three of the subjects dropped out during the run-out period due to a history of
respiratory tract infection (#5 and #6), or because of taking an anti-histamine (#11).
Three subjects (#9, #18 and #23) did not produce adequate sputum at baseline, whilst
subject 21 and 7 were not able to produce sputum at week 2 and week 4, respectively
These time points were handled as missing data.
Lung function and histamine challenge
At baseline there were no significant differences in FEV1 and PC20 between the groups
(p>0.19; table 1). During the study there were no significant changes in FEV1 in the two
groups (p>0.96, MANOVA). In the placebo group there were no significant changes in
PC20 (p = 0.92, MANOVA) while in the steroid treated group PC20 increased significantly at
week 4 compared with baseline values (mean change 2.01 (95% CI 0.683 to 2.090); p =
0.001; fig 1). After a two week washout period PC20 decreased again compared with week 4
by –1.75 (–1.831 to –0.582) doubling doses (p = 0.002; table 2, fig 1). These changes were







Figure 1. Airway hyperresponsiveness
to histamine (PC20) at baseline, at 2
and 4 weeks of treatment, and after 2
weeks wash-out in steroid (closed
bars) and placebo group (open bars).
shown as geometric mean doubling
dose. * = significant difference
between the two groups.
Sputum eosinophils
The mean (SD) percentage of squamous cells in this study was 33.4 (17.6)%. Baseline
sputum eosinophils were not significantly different in the two groups (p = 0.31; table 1).
There were no significant changes in sputum eosinophils within the placebo group (p =
0.85, MANOVA), but in the steroid treated group a significant decrease in sputum
eosinophils was observed compared with baseline values (mean change at week 4 –2.46
(95% CI –4.260 to –0.660)%; p = 0.01) with a subsequent worsening in the washout
period compared with week 4 (mean change 6.13 (95% CI 0.804 to 11.459)%; p = 0.03;
table 2, fig 2). The changes in sputum eosinophils were not significantly different
between the two groups when baseline values were compared with week 4, or week 4
values were compared with those in the washout period (table 3).
Exhaled NO
At baseline exhaled NO levels were not significantly different in the two groups (p =
0.55; table 1). During the study there were no significant changes in exhaled NO levels
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Table 2. Airway hyperresponsiveness, sputum eosinophils and exhaled NO during and after steroid
and placebo treatment
Baseline Week 2 Week 4 Run-out
Steroid group
PC20 (mg/ml) 0.91 (1.62) 3.19 (1.54)
¶ 3.67 (1.05)¶ 0.93 (1.50)§
Eosinophils (%) 3.40 (0.00,7.60) 0.30 (0.00,3.00)¶ 0.20 (0.00,1.60)¶ 4.41 (1.40,20.00)§
NO (ppb) 5.57 (2.15,11.81) 1.54 (0.11,4,86)¶ 1.48 (0.59,3.68)¶ 3.50 (0.90,12.89)§
Placebo group
PC20 (mg/ml) 0.52 (1.38) 0.64 (1.21) 0.59 (1.86) 0.66 (1.26)
Eosinophils (%) 1.20 (0.00,24.60) 1.20 (0.00,18.56) 3.47 (0.00,16.60) 3.75 (0.60,30.00)
NO (ppb) 5.82 (2.48,14.08) 5.03 (0.59,18.73) 5.26 (0.17,11.38) 5.36 (1.94,21.28)
Values of PC20 expressed as geometric mean (SD) in DD, values of sputum eosinophils and exhaled
NO expressed as median (range), ¶p<0.01 as compared to baseline, §p<0.01 as compared to week 4
Figure 2. Mean eosinophil
counts in induced sputum at
baseline, at weeks 2 and 4 of
treatment, and after 2 weeks
of wash-out in steroid treated
(closed bars) and placebo
groups (open bars). * =
significant difference between
the two groups.
in the placebo group (p = 0.54, MANOVA; table 2) but in the steroid treated group the
levels of exhaled NO decreased significantly at week 4 compared with baseline values
with a mean change of –4.88 (95% CI –6.862 to –2.892) ppb (p < 0.001), with a
subsequent increase during the washout period compared withweek 4 of 3.65 (95% CI
0.882 to 6.423) ppb (p = 0.016; table 2, figure 3). These changes in exhaled NO levels
were significantly different from the changes in the placebo group between baseline and
week 4 (p = 0.005; table 3).
Relationship between observed changes
Within the steroid group there were no significant correlations between the changes in








Table 3. Comparison of change in airway hyperresponsiveness, sputum eosinophils and exhaled
NO between steroid and placebo treatment
Baseline – Week 2 Baseline – Week 4 Week 4 – Run-out
 PC20 (mg/ml)
Steroid 1.80 (1.38) 2.01 (1.60) -1.75 (1.17)
Placebo 0.32 (0.59) 0.19 (0.97) 0.17 (1.15)
p-value 0.004 0.003 0.001
 Sputum eosinophils (%)
Steroid –1.40 (-7.60,0.40) -1.90 (-7.60,0.00) 2.81 (1.40,18.80)
Placebo 0.20 (-18.80,9.80) 1.00 (-11.40,11.20) 0.82 (-7.45,20.80)
p-value 0.13 0.03 0.15
 Exhaled NO (ppb)
Steroid -3.81 (-10.10,-1.09) -3.89 (-9.90,-0,75) 2.12 (0.16,9.21)
Placebo -0.62 (-2.67,4.65) -1.71 (-5.15,1.09) 0.40 (-1.21,10.76)
p-value 0.0001 0.007 0.049
Values of changes PC20 expressed as geometric mean (SD) in DD, values of changes in sputtum
eosinophils and exhaled NO expressed as median (range)
Figure 3. Mean levels of
exhaled nitric oxide (NO) at
baseline, at weeks 2 and 4 of
treatment, and after 2 weeks
of wash-out in the steroid
treated (closed bars) and
placebo groups (open bars). *
= significant difference
between the two groups.
Discussion
The results of this study indicate 4 weeks of therapy by inhaled steroids lead to
improvements in airway hyperresponsiveness, sputum eosinophils, and levels of exhaled
NO in patients with mild atopic asthma. In addition, it appears that the improvement in
these markers are lost 2 weeks after cessation of treatment. This suggests that each of
these markers is useful for monitoring patients with asthma, even though there might be
small differences between the markers in the earliest response to anti-inflammatory
treatment.
To our knowledge this is the first study comparing the treatment-induced changes in
airway hyperresponsiveness to histamine, eosinophils counts in induced sputum, and
exhaled NO in a group of asthmatic patients. Our study confirms and extends the results
of others who have demonstrated the beneficial effect of glucocorticoids on each of
these markers separately. In accordance with Kraan et al., we showed an improvement of
2 doubling doses in airway hyperresponsiveness after 4 weeks of treatment with inhaled
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Figure 4. Relationship between
the change in sputum eosinophils
and the change in PC20 histamine
at week 4 compared with baseline
(closed circles = steroid group;
open circles = placebo group).
Figure 5. Relationship between
the change in exhaled NO levels
and the change in PC20 histamine
at week 4 compared with baseline
(closed circles = steroid group;
open circles = placebo group).
steroids (20). Furthermore, our findings are in agreement with those of Keatings et al.
(12) and Kharitonov et al. (14), who demonstrated a decrease in sputum eosinophils and
exhaled NO, respectively, after inhaled steroid treatment.
Although cross-sectional relationships between airway hyperresponsiveness, sputum
eosinophils and exhaled NO in asthma have been previously reported (10,21), there are
only limited data on the comparison of within-subject changes in these markers during
treatment follow-up. Our results are in agreement with those of Baraldi et al. who also
failed to demonstrate a correlation between steroid-induced changes in PD20 and
sputum eosinophils (22). The absence of such relationships may reflect the partially
distinct pathophysiological backgrounds of these markers, and might be indicative of
possible independent, complementary clinical information during anti-inflammatory
therapy.
We do not believe that our data were influenced by measurement errors, since we used
validated and reproducible methods (6,7,17,19). All subjects in this study were carefully
selected to be non-smokers with stable, atopic asthma, who had not used inhaled steroids
for at least 1 month prior to the study. We had chosen a relatively high dose of inhaled
steroids as the present intervention in order to ensure an optimal anti-inflammatory
effect. To avoid carry-over effects, the histamine challenge for determination of PC20 and
the sputum induction were separated by 2-4 days. Furthermore, exhaled NO levels at
these two days appeared to be highly reproducible. Our inability to demonstrate
significant improvement in lung function following steroid treatment may be due to the
normal baseline levels of FEV1 in our study (77-111% of the predicted value).
How can the present findings be interpreted? First, glucocorticoids are likely to decrease
the percentage sputum eosinophils by reducing the release and effects of cytokines like
interleukin-5 (IL-5) and granulocyte-macrophage colony-stimulating factor (GM-CSF) on
eosinophil infiltration and survival (23-25). Second, the steroid-induced reduction in
exhaled NO can be explained by the inhibition of inducible NO synthase (iNOS)







Figure 6. Relationship between
the change in sputum eosinophils
numbers and the change in
exhaled NO levels at week 4
compared with baseline (closed
circles = steroid group; open
circles = placebo group).
for instance in epithelial cells (26). Finally, the improvement in the physiological marker,
PC20, is likely to be due to effects of steroids on the presence and activity of multiple
(infiltrative and resident) cells (5,8,9,27). Hence, it may not be surprising that the
steroid-induced changes in the three markers were not significantly correlated to each
other. Apparently, the earliest improvements of eosinophils in response to steroid
treatment is somewhat out of phase as compared to the other two markers. However we
believe that this has little implications, given the consistency in the changes between the
markers after 4 weeks of treatment.
What are the clinical implications of the present findings? Treatment according to the
current international guidelines is based on minimising symptoms and optimising lung
function (1). However, frequently, this fails to provide complete suppression of airway
inflammation (5). It has been postulated that persistent airway inflammation in asthma
leads to airway remodelling and an irreversible loss of lung function (28,29). This may
require the use of more direct markers for monitoring airway inflammation (10,30).
Indeed, a recent study by Sont et al. demonstrated that the adjustment of long-term
inhaled steroid treatment, additionally guided by the level of airway
hyperresponsiveness, leads to a significantly better clinical, as well as histological,
outcome as compared to treatment based on symptoms and lung function alone (31).
Based on the present data, it needs now to be addressed in long-term prospective trials as
to whether monitoring sputum eosinophils and/or exhaled NO can provide similar
benefits in asthma management.
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Assessment of microvascular leakage via
sputum induction: the role of substance P
and neurokinin A in patients with asthma
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Abstract
Background Microvascular leakage is an important feature of inflammation. However,
the assessment of vascular leakage has seldom been used to monitor airway inflammation
in asthma. The aim of this study was to determine the effect of inhaled substance P, a
potent NK1-agonist and mediator of plasma extravasation, on markers of microvascular
leakage in induced sputum in patients with asthma.
Methods In a cross-over study, sputum was induced before and 30 min. after inhalation
of substance P or neurokinin A (as control) in 12 atopic and mild, steroid-naive
asthmatic subjects. The levels of alpha-2-macroglobulin, ceruloplasmin, albumin, and
fibrinogen were determined in induced sputum as markers of leakage.
Results Substance P induced a significant increase in the levels of alpha-2-macroglobulin,
ceruloplasmin, and albumin in induced sputum (median fold change 3.1, 2.2 and 2.9,
respectively) (p < 0.013), whereas inhaled neurokinin A was not able to induce
significant changes (p>0.31). The increase in sputum leakage markers was not associated
with the cumulative dose of substance P (p>0.12).
Conclusion These results indicate that NK1-receptor stimulation causes a rapid increase
in microvascular leakage as shown in induced sputum in patients with asthma. This
investigational model of “dual induction” (first leakage, then sputum) may therefore be
useful to test the anti-exudative effect of newly develop drugs, such as NK1-antagonists.
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Introduction
Asthma is a chronic disease of the airways, characterized by variable airway obstruction
and airway hyperresponsiveness to various stimuli (1). Mucosal inflammation of the
airways can be considered as one of the major components of asthma (2). The role of
cell activation and the subsequent release of mediators in this inflammatory process has
been extensively studied (2). On the other hand, microvascular leakage and edema are
also prominent features of airways inflammation in asthma (3). Remarkably, leakage has
not often been measured to monitor inflammation in asthma, which is probably due to
the difficulties of the measurement in bronchial tissue specimens and luminal fluids.
Thus far, there are only few studies demonstrating the effect of treatment intervention
on leakage parameters in asthma (4).
In animal models, several inducers of airway microvascular leakage have been identified
(5). Amongst these, the tachykinin substance P (SP) appears to be one of the most
potent mediators causing leakage in guinea pig airways (6). It is likely that tachykinins
play a role in the pathogenesis of asthma. Tachykinins have been detected in airway
sensory nerves and in secretions recovered from human airways (7). More importantly,
elevated levels of SP have been demonstrated in BAL fluid and sputum, and a further
increase occurred following allergen challenge in patients with asthma (8;9). In human
tissue, the distinct NK1- and NK2-tachykinin receptors have recently been identified
using immunohistochemistry (10). The NK2-receptor mediates smooth muscle
contraction in human airways (11), whereas the NK1–receptor primarily induces pro-
inflammatory effects: plasma extravasation, mucus secretion, inflammatory cell
chemotaxis and activation (7). Interestingly, NK1- and NK2-receptor mRNA expression
appears to be increased in asthmatics as compared to normals (12;13).
It is still unknown whether NK1-stimulation leads to microvascular leakage in the airways
of asthmatics in vivo. So far, SP-induced effects on microvascular leakage have only been
demonstrated in the airways of guinea pigs (14). In humans in vivo, both neurokinin A
(NKA) and SP cause airway narrowing, particularly in patients with asthma (15). This
may predominantly be due to NK2-mediated smooth muscle contraction (11). In
addition, inhaled SP enhances airway hyperresponsiveness, as demonstrated by an
increase in the maximal response to inhaled methacholine in asthmatic patients in vivo
(16). We postulate that this is associated with an NK1-mediated increase in microvascular
permeability in the airway wall. 
Therefore, in the current study, we investigated whether inhaled SP induces
microvascular leakage in asthmatic patients in vivo. To that end, we determined the levels
of albumin, fibrinogen, ceruloplasmin and alpha-2-macroglobulin as markers of leakage
in induced sputum before and after SP challenge in patients with asthma. Since
challenges with methacholine or histamine are known to induce leakage (17), inhaled
NKA was used as a control challenge, in order to compare the leakage markers in









Twelve non-smoking atopic asthmatic volunteers (8 female, 20-26 years) participated in
the study (Table 1). All subjects had a history of episodic chest tightness and wheezing
and none was using medication except for short-acting ß2-agonists as needed. Atopy was
determined by a positive response to a standardized skin prick test with 10 common
allergens (Vivodiagnost, ALK, Benelux). The baseline forced expiratory volume (FEV1)
was > 80% predicted (18) and all subjects were hyperresponsive to inhaled histamine
(provocative concentration causing a 20% fall in FEV1 (PC20) <4 mg/ml) (19). All
patients were clinically stable and had no history of recent allergen exposure or
respiratory chest infection. The study was approved by the medical ethics committee of
the Leiden University Medical Center and all volunteers gave a written informed
consent.
Design
The study had a single blind randomized, cross-over design. At least one week before
entering the study, inclusion and exclusion criteria were examined and PC20 histamine
was determined. Inhaled SP or NKA challenge was performed on two randomized study
days with an interval of at least one week. Sputum was induced 2 days before and 30
minutes following the SP or NKA challenge. In addition, a venous blood sample was
obtained before each sputum induction.
Inhalation challenges
Histamine challenge was performed according to a standardized procedure (19) using
the tidal breathing method. SP and NKA challenges were performed according to a
previously validated protocol (16;20;21). SP (Sigma, St. Louis, USA) was inhaled in serial
doubling concentrations (0.25 - 8 mg/ml) and NKA (Bachem, Budendorf, Switzerland)
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Table 1. Characteristics of the subjects
Subject no Sex (F/M) Age (years) FEV1 (%pred) PC20 his (mg/ml)
1 F 23 86.0 0.20
2 F 23 87.7 0.65
3 F 22 96.0 0.74
4 F 23 100.8 0.98
5 M 22 100.0 1.37
6 M 21 91.4 1.76
7 F 24 102.5 1.82
8 F 18 102.6 1.89
9 F 20 80.6 2.03
10 M 26 82.8 2.19
11 M 24 82.1 2.73
12 F 24 105.9 3.90
22.5 (2.11)* 93.2 (9.13)* 1.35 (1.15)†
FEV1 = forced expiratory volume in one second; PC20his = provocative concentration of histamine
causing a 20% fall in FEV1; * mean (SD), † geometric mean (SD in doubling doses).
in concentrations between 8 and 1000 mg/ml. SP and NKA were aerosolized by a jet-
nebulizer into a collapsible bag (Mallinckrodt, Petten, The Netherlands) (22). The
aerosols were subsequently inhaled by tidal breathing for 3-4 min. at 7 min. intervals.
The airway responses to SP and NKA were measured using FEV1 (18), at 90 and 180
seconds after each dose (16). Additionally, systolic and diastolic blood pressure were
monitored after each dose. Both challenges were discontinued when PC20 was reached
(FEV1 dropped by 20% from baseline).
Sputum induction and processing
Prior to induction, each subject inhaled 200 µg salbutamol. Sputum was induced by
inhalation of NaCl 4.5% during 3x5 minutes intervals, according to a recommended
protocol validated in our lab (23;24). Sputum samples were processed according to a
validated method (24). An equal volume of 0.1% w/v dithiotreitol was added to the
whole sample. Supernatant was aspirated following centrifugation and the total cell
counts were determined. Differential cell counts were expressed as a percentage of 250
non-squamous cells (24).
Measurement of microvascular leakage
Fibrinogen was measured in coded sputum samples using a commercially available
ELISA (Kordia, Leiden, The Netherlands) and albumin was determined by rate
nephelometry (24). The concentrations of alpha-2-macroglobulin and ceruloplasmin in
sputum and serum were measured by ELISA. Commercially available antibodies for
alpha-2-macroglobulin (code A033) and ceruloplasmin (code A031) were obtained from
DAKO (DAKO, Glostrup, Denmark) (25;26). To correct for protein concentrations in
blood, sputum-to-serum ratios were determined as follows: sputum-protein
(mg/l)/serum-protein (g/l) (26).
Analysis
The PC20 for histamine, SP and NKA were log transformed before statistical analysis and
expressed as geometric mean (SD in doubling doses) The markers of microvascular
leakage were expressed as median (range). Wilcoxon Signed Rank test was applied to
test for differences before and after, and between challenges. Correlations were analysed
using Spearman rank test. A p-value of < 0.05 was used as statistical significance and all
analysis were performed using SPSS 10.0.
Results
Two subjects (nos. 7 and 12) did not produce sputum after the NKA challenge, whilst
subject 8 was not able to produce sputum following SP. These time points were handled
as missing data. Neither SP nor NKA had a significant effect on systolic or diastolic blood
pressure (data not shown), though most subjects experienced transient flushing and
warmth after 4 and 8 mg/ml SP. The geometric mean value (SD in doubling doses) for







consequence, the molar concentration to reach PC20 was 7.5 fold higher for SP than for
NKA. There was a moderate correlation between the PC20 values for NKA and histamine
(Rs = 0.59, p = 0.04), whereas neither of these correlated with PC20 SP (Rs < 0.19, p >
0.56). The maximal drop in FEV1 following SP- and NKA challenge was similar (median
(range) 25.4 (20.0-30.6) and 24.0 (20.0-28.4) %fall from baseline, respectively) (p =
0.31). There were no significant changes in the differential cell counts 30 minutes after
the SP or NKA challenge (p > 0.09). Furthermore, total cell counts per gram sputum
were not altered by the challenges (p > 0.11) (Table 2).
Markers of microvascular leakage
There were no significant differences in the baseline levels of all sputum markers
between the SP- and the NKA challenge days (Table 3) (p > 0.44). The concentrations of
alpha-2-macroglobulin, ceruloplasmin and albumin in sputum increased markedly 30
minutes following SP as compared to before the challenge (median fold change 3.1, 2.2
and 2.9, respectively) (p < 0.013) (Figure 1; Table 3). In contrast, there were no
significant changes in these markers after NKA challenge (median) fold change 1.0, 1.0
and 1.1 (p > 0.31) (Figure 1). Neither SP nor NKA had a significant effect on the levels
of fibrinogen in sputum (median fold change 1.4 and 1.5, respectively) (p > 0.29)
(Figure 1d). At 30 min following challenge, the levels of alpha-2-macroglobulin were
significantly higher after SP as compared to NKA (p = 0.028) (Figure 1a) (Table 3). The
sputum-to-serum ratios for alpha-2-macroglobulin, ceruloplasmin and albumin increased
significantly after the SP challenge (median prior to post challenge 1.22 to 2.94, 3.83 to
7.26 and 2.94 to 10.72, respectively) (p < 0.021), but not after the NKA (1.14 to 1.56, 2.77
to 5.21 and 2.94 to 5.34) (p > 0.33). The alpha-2-macroglobulin sputum-to-serum ratio
following SP challenge was higher than after the NKA challenge (p = 0.05). The
cumulative dose of inhaled SP was (median (range)) 1.88 (0.13-6.38) mg and for NKA
121.10 (27.35-996.10) mg. These cumulative doses were not correlated with the
percentage increase in sputum leakage markers (p>0.12) or sputum-to-serum ratios
(p>0.08). Furthermore, there was no relationship between the maximal % fall in FEV1
following SP or NKA and the rise in leakage markers (p>0.10) or sputum-to-serum ratios
(p>0.17).
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Table 2. Differential cell counts in induced sputum
Neurokinin A Substance P
pre post pre post
macrophages (%) 48.6 (9-82) 45.2 (24-77) 52.2 (34-77) 35.0 (14-82)
neutrophils (%) 36.1 (6-72) 38.9 (16-59) 27.8 (15-59) 41 (15-78)
eosinophils (%) 1.3 (0-18) 2.8 (0-30) 2.2 (0-21) 1.8 (0-32)
lymphocytes (%) 1.6 (0-6) 2.0 (0-8) 1.6 (0-10) 2.4 (0-13)
epithelial cells (%) 6.8 (1-45) 5.3 (1-18) 5.6 (3-35) 5.2 (2-25)








Table 3. Markers of microvascular leakage in induced sputum
Neurokinin A Substance P
pre post pre post
2-macroglobulin 4.8 6.2 3.2 14.9*†
(µg/ml) (0.4-25.5) (0.4-41.1) (0.4-22.1) (0.4-139.9)
Ceruloplasmin 0.56 0.65 0.62 1.70*
(µg/ml) (0.2-3.3) (0.2-5.2) (0.2-3.5) (0.2-4.9)
Albumin 132.7 238.8 141.2 471.6*
(µg/ml) (19.6-1889.6) (25.8-1795.6) (21.6-629.4) (83.4-1834.0)
Fibrinogen 13.1 12.9 12.2 16.4
(µg/ml) (1.0-28.7) (1.6-44.1) (1.9-41.4) (3.6-44.2)
* p-value < 0.013 compared with pre-challenge; † p-value = 0.028 compared with post NKA-
challenge. Data are expressed in median (range)
Figure 1. Markers of microvascular leakage in induced sputum pre and 30 min. post inhalation of
neurokinn A or substance P.
a) alpha-2-macroglobulin in µg/ml; b) ceruloplasmin in µg/ml; c) albumin in µg/ml;




This study has shown that inhaled substance P induces a rapid increase in the levels of
alpha-2-macroglobulin, albumin and ceruloplasmin in induced sputum in patients with
asthma. In contrast, inhaled neurokinin A was not able to induce such changes. These
results indicate that NK1-receptor stimulation enhances microvascular leakage in the
airways of patients with asthma in vivo, whereas NK2 stimulation does not. Furthermore,
it becomes apparent that induced sputum can be a suitable method of monitoring
microvascular leakage as a component of airways inflammation in asthma. 
This is the first study examining the effects of SP on microvascular leakage in humans in
vivo. Similar results have been found in previous animal studies. Lötvall et al. have
demonstrated in guinea pigs, that microvascular leakage in the airways occurred after
aerosolized SP (14), which appears to be inhibited by a selective NK1 receptor antagonist
(27). In addition, the presently observed absence of leakage following NKA inhalation is
also in agreement with results reported in guinea pig airways (28). Interestingly, our data
demonstrate that induced exudation can be measured using induced sputum. This
confirms and extends the findings by Halldorsdottir et al., who have shown that inhaled
histamine induces a comparable increase in the levels of alpha-2-macroglobulin in
induced sputum (17).
It seems unlikely that the present findings can be explained by measurement errors,
since the data were obtained by using validated methods of performing SP and NKA
challenge (16;21), sputum induction and processing (24) and determination of 
markers of microvascular leakage (25). All subjects were non-smokers, and were 
having clinically stable asthma without using steroids. Furthermore, we have applied a
cross-over, randomized design, using NKA as a control challenge. This allowed
comparison of the leakage markers between distinct stimuli at a given degree of
bronchoconstriction. 
We have chosen NKA instead of histamine or methacholine challenge, because these
mediators have previously been shown to induce an increase in alpha-2-macroglobulin
(17). Moreover, NKA is a tachykinin and therefore member of the same family of
neuropeptides as SP. For each of these agonists the receptors have been demonstrated
within human airways (10), and by using these two tachykinins we aimed to distinguish
preferential NK1- and NK2-stimulation within the airways (7;29). Though, only when
using selective receptor antagonists, it would be possible proof the unique involvement
of the NK1 receptor in our model (30). With selective antagonists, it has indeed been
demonstrated that stimulation of the NK1-receptor induces microvascular leakage,
whereas the NK2-receptor exerts its effects on bronchoconstriction in man and animals
(31;32). We can not exclude that the differences between SP and NKA in inducing
microvascular leakage are related to the 7.5-fold difference in molar concentrations
between these compounds required to reach the PC20. Therefore, we may have missed a
potential possitive effect of NKA due to the lower concentration nebulized. However, the
absence of relationships between the doses of SP or NKA and the increase of leakage
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markers in sputum does not favour such explanation. In addition, similar differences
between SP and NKA in potency have been found in animal models (33).
We had chosen to start sputum induction at 30 minutes after the challenges, based on
the study of Halldorsdottir et al. (17), who demonstrated an increase in alpha-2-
macroglobulin in sputum 45 minutes following a histamine challenge. It can be argued
that the extravasation of plasma occurs earlier, based on the rapid effect of mediators on
microvascular permeability (5). This would imply that the maximal increase in these
markers, is even more pronounced than we observed. The time-course of leakage may
also explain why we did not observe a significant SP-induced increase in the levels of
sputum fibrinogen. It can not be excluded that the leakage of fibrinogen occurred at an
earlier time point and had dissipated by the time of the sputum induction. Furthermore,
after escaping the vasculature, fibrinogen could polymerize into fibrin and thereby
cannot gain access to the airway. A recent study of Peebles et al., also failed to show
plasma extravasation, as demonstrated by fibrinogen in BAL, 24 hours following an
allergen challenge in patients with asthma (34).
The SP-induced increase in permeability of the airways appears to be associated with the
formation of small interendothelial pores. Subsequently, the extravasating bulk plasma is
moving through these pores into the airway lumen, which is likely to be driven by an
increase in hydrostatic pressure (35). Hirata et al. have demonstrated that injection of SP
causes the formation of intercellular gaps between endothelial cells in postcapillary and
collecting venules of rat trachea (36). Microvascular leakage in vitro can be reduced
using cAMP elevating drugs e.g. PDE inhibitors and formoterol by inhibiting endothelial
gap formation (37;38). In healthy subjects, such anti-exudative effect of formoterol
could indeed be confirmed in sputum, indicating that this mechanism plays a role in
humans in vivo (4).
What are the clinical implications of our findings? The SP-induced increase in
microvascular leakage in our study suggests that the phenomenon of neurogenic
inflammation can be relevant in asthmatics in vivo. Indeed, elevated levels of SP have
been found in BAL and sputum of patients with asthma (8;9). In particular, during
unstable episodes of asthma, NK1-activity seems to have functional significance, for
instance, during cold air-, virus- (39) or allergen- (40) induced plasma extravasation.
Taken together, this implicates that NK1-receptor antagonists may reduce microvascular
leakage in asthma and thereby could have beneficial effects in the treatment of asthma.
Using the current investigational model of “dual induction”, that is induced exudation
and induced sputum, it will be possible to demonstrate microvascular leakage in humans
in vivo. Therefore, this method can be applied when testing the anti-exudative effect of
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Abstract
Background Patients with asthma have an accelerated decline in lung function, which
can lead to irreversible airway obstruction. It is generally assumed that this is related to
specific aspects of airway inflammation and/or remodelling. We investigated the
prognostic significance of bronchial eosinophil and CD8+ cell counts and subepithelial
reticular layer thickness for the subsequent decline in lung function in patients with
asthma after 71⁄2 years of follow-up.
Methods In a prospective study, pre- and post-bronchodilator lung function (FEV1) was
measured at baseline, after 2 years and 71⁄2 years in 32 patients with asthma. Annual
decline in lung function after 71⁄2 years of follow-up was related to type and severity of
airway inflammation and remodelling in bronchial biopsies, which were taken at
baseline and at year 2.
Results Annual decline in post-bronchodilator FEV1 (mean (SD) 46.6 (53.4) ml/yr) was
significantly larger than the decline in pre-bronchodilator FEV1 (mean (SD) 27.5 (62.5)
ml/yr), indicating loss in reversibility. Whereas, annual fall in post-bronchodilator 
FEV1 was not related to thickness of the reticular layer or to eosinophil counts in
bronchial biopsies, there was a significant correlation with CD8 positive T-cells 
(r=-0.39;p=0.032). Analyzing the biopsies taken at year 2, the significant association
between annual fall in post-bronchodilator FEV1 and CD8 cells could independently be
confirmed(r=-0.39;p=0.036).
Conclusion The outcome of asthma, as determined by the annual decline in FEV1, can
be predicted by the bronchial CD8+ cell infiltrate. This suggests that the inflammatory




Asthma is a chronic inflammatory disease that is characterized by variable airway
obstruction to various inhaled stimuli (1). Although this is largely reversible in most
patients, some asthmatics develop persistent non-reversible airway obstruction despite
adequate treatment (2). Longitudinal studies have shown that adult patients with asthma
have an accelerated decline in lung function (FEV1) as compared to controls (3-5).
However, the rate of decline demonstrates large variability between patients, which seems
to be associated with disease duration, baseline lung function and airway responsiveness
(6;7). Eventually, the lung function decline may progress to irreversible airway
obstruction in a subgroup of patients with asthma (8).
The current working hypothesis is that chronic inflammation promotes restructuring of
the airways, which in turn results in accelerated decline in lung function in some but not
all asthmatics. Airway inflammation in asthma is characterized by infiltration of
lymphocytes and eosinophils in the bronchial epithelium and lamina propria (9) and of
mast cells in the smooth muscle layer (10). Due to the release of growth factors and
other mediators, the infiltrate is thought to induce structural changes in the bronchial
wall often referred to as tissue remodelling (11). Since this process begins early in the
development of asthma, remodelling may occur in parallel or could even be required for
the development of persistent inflammation (12). The features of airway remodelling in
asthma include thickening of the sub-epithelial reticular layer, changes of the interstitial
matrix composition, increases in blood vessel area, airway smooth muscle, goblet cells in
the surface epithelium and number of mucous glands (11). 
The prognostic significance of airway inflammation and remodelling for the decline in
lung function is still unclear. In patients with chronic obstructive pulmonary disease
(COPD) fixed airway obstruction is often found to be associated with bronchial CD8+ T
cell infiltration (13;14). Cross-sectional studies in severe asthma have demonstrated that
sputum and tissue eosinophil counts are associated with a lower lung function (8;15).
Furthermore, in some (16;17), but not all studies (15), the thickness of the sub-epithelial
reticular layer was inversely associated with the level of lung function in asthma.
However, it remains questionable whether these cross-sectional associations hold after
longitudinal follow-up.
We postulated that the type and severity of inflammation or remodelling in bronchial
biopsies are predictive of the subsequent annual decline in lung function in patients with
asthma. For this reason, we performed a prospective follow-up study in a previously
reported group of patients with asthma (AMPUL-cohort) (18) who underwent repeated
bronchoscopies and extensive clinical measurements at baseline. We aimed to investigate
the relationship of bronchial eosinophil and CD8+ cell counts and the thickness of the
sub-epithelial layer as measured at baseline with the subsequent annual decline in lung









75 Atopic patients with mild-moderate persistent asthma participated in the study (18).
45 Patients underwent a successful bronchoscopy at entry and 37 patients at t=2 years. At
inclusion, all patients (18-50yr) were non- or ex-smokers (< 5 pack-years), all had
symptoms of episodic chest tightness and wheezing, whilst 77% of patients was using
regular inhaled steroids. Pre-bronchodilator forced expiratory volume in one second
(FEV1) was >50% of predicted and >1.5L, whilst post-bronchodilator was within the
normal range (>80% predicted)(20). All patients were hyperresponsive to methacholine
(provocative concentration causing 20% fall in FEV1 (PC20) <8mg/ml). The medical
ethics committee of the Leiden University Medical Center approved the study and all
participants gave written informed consent.
Design
In a prospective study design, pre- and post-bronchodilator FEV1 and PC20 were
measured at baseline, at years 2 and 71⁄2. Bronchoscopies were performed at baseline and
year 2. During the first two years patients were treated according to standardized
guidelines, and treatment was adjusted by a chest physician every 3 months (18). In
order to make this study representative for daily practice, the own physician of each
patient was instructed to adjust treatment according to Dutch GINA-derived guidelines
between 2 and 71⁄2 years of follow-up.
Spirometry and airway responsiveness
Spirometry was performed according to the same procedures throughout the study (18).
Patients withheld short-acting ß2-agonists for 8 hours and long-acting ß2-agonists for at
least 24 hours prior to the measurements. Post-bronchodilator FEV1 was measured 15
minutes following inhalation of 400 µg salbutamol (20). Airway hyperresponsiveness was
determined using a methacholine challenge and was expressed as PC20.
Bronchoscopy and immunohistochemistry
At baseline and after 2 years five bronchial biopsies were taken for electron and light
microscopy from right lower lobe subsegments, the middle lobe and the main carina
using a pair of cup forceps (Olympus FB-21C, Japan). Two biopsies were fixed
immediately in Trump’s fixative and ultra thin sections were processed for electron
microscopy. The thickness of the sub-epithelial reticular basement membrane was
determined by measuring area divided by length on electron microscopy pictures in 2-5
well oriented electron micrographs (X5700, 35x42mm), using computerized
analysis(18). Three biopsies were immediately embedded in ornithyl carbamyltransferase
medium and snap-frozen in isopentane. Immunohistochemistry was performed on 6mm
cryostat sections. Sections were stained with monoclonal antibodies against EG2
(eosinophils) (Pharmacia, Sweden), and CD8+ cells (Becton Dickinson, USA).A
validated method using computerized analysis was applied to examine the coded biopsy
specimens(21). Two areas were selected and the number of positively stained cells was
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determined in the lamina propria. Values were expressed as cells/0.1 mm2. Detailed
biopsy methods and cell number data, including AA1 (mast cells), CD3 and CD4+ cells,
have been previously published(18).
Analysis
Post-bronchodilator FEV1 was applied in the analysis in order to minimize the
contribution of varying degrees of smooth muscle contraction to the level of airway
obstruction. The decline in post-bronchodilator FEV1 was determined between baseline
and t=71⁄2 years (FEV1 at 7
1⁄2 years – FEV1 at baseline / 7
1⁄2) and between t=2 and t=71⁄2 years
(FEV1 at 7
1⁄2 years – FEV1 at 2 years / 5
1⁄2) and was expressed as annual decline in
ml/years. The declines in pre- and post-bronchodilator FEV1 were compared using a
paired t-test. Linear regression analysis was used to investigate the association between
inflammation (EG2 and CD8 positive cells and reticular layer thickness) in bronchial
biopsies and annual decline in post-bronchodilator FEV1 during follow-up.
Results
Patient characteristics
Thirty-two of the 45 patients who underwent the bronchoscopy at baseline, participated
at follow-up after 71⁄2 years (71% response rate) [table 1]. The participating patients were
not different from the non-participants with respect to disease severity, spirometry,
reticular layer thickness, EG2 and CD8+ cells (p>0.2). In 30 of these 32 patients biopsies
were also taken at year 2. The total follow-up period was 7.6 (0.6) (mean (SD)) years. At
all three time points, about 70% of the patients were using inhaled steroids [table 2].
None of the patients were using long-acting ß2-agonists at t=0 and t=2, compared to six
patients at t=71⁄2 years. Seven patients stayed under regular control of a chest physician,
whereas 23 patients were treated by a general practitioner. Only 2 patients stopped using
any asthma medication and were free of symptoms. During the follow-up period, 1 in 5
received treatment with one or more courses of oral corticosteroids. Two patients had
become current smokers after 71⁄2 years, whereas none smoked during the first two years.
PC20 methacholine was <8 mg/ml in all patients at baseline, and in 28 of the 32 patients
at t=71⁄2 (range 0.02 to 16.3 mg/ml) [table 2].
Lung function decline
The mean pre- and post-bronchodilator FEV1 in % predicted stayed within the normal
range at all visits with considerable scatter [table 2]. The annual decline in pre-
bronchodilator FEV1 during follow-up was (mean (SD)) 27.5 (62.5) ml/yr, whereas the
annual drop in post-bronchodilator FEV1 was 46.6 (53.4) ml/yr [figure 1]. The variability
in decline in post-bronchodilator FEV1 between individual patients was large, ranging
from an annual increase by 39 ml/yr to an annual fall by 149 ml/yr. The decline in post-
bronchodilator FEV1 was significantly larger than in pre-bronchodilator FEV1 (p=0.022),







Prognostic significance of airway inflammation
The annual decline in post-bronchodilator FEV1 during the follow-up period was not
related to thickness of the bronchial subepithelial reticular layer at t=0 (r=-0.02; p=0.92)
[figure 2]. In addition, the fall in post-bronchodilator FEV1 during follow-up showed no
correlation with eosinophils at baseline (r=0.02;p=0.90). On the other hand, the annual
change in post-bronchodilator FEV1 during the follow-up period of 7
1⁄2 years was
significantly and inversely correlated with the bronchial CD8+ cells at t=0 (r=-
0.39;p=0.032). The slope of the linear regression analysis showed that for each doubling
in CD8+ cells, post-bronchodilator FEV1 declined with an additional 13.8 ml/yr. When
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patients were unable to




71⁄2 years of follow-up
6 lost to follow-up
2 no consent
3 unable due to time







Table 2. Patient characteristics
baseline t=2 years t=71⁄2 years
age (years) 30.8 (8.9)
follow-up (years) 2.0 (0.0) 7.6 (0.6)
inhaled steroids (% patients) 72% 75% 69%
pre-bronchodilator FEV1 (% pred.) 87.2 (13.4) 86.3 (14.0) 84.7 (16.9)
post-bronchodilator FEV1 (% pred.) 99.3 (11.0) 96.7 (12.6) 93.2 (15.8)
PC20 methacholine (mg/ml)* 0.67 (2.2) 0.88 (1.73) 0.91 (2.8)







Figure 1. Left panel: mean pre-bronchodilator (closed circles) and post-bronchodilator (open
squares) FEV1 at baseline (t=0) and at follow-up (t=7
1⁄2 years). Right panel: annual decline in FEV1
from baseline to follow-up for pre-bronchodilator (black bar) and post-bronchodilator (white bar).
Figure 2. Left panel: associations of annual change (year 0 to 71⁄2) in post-bronchodilator FEV1 with
reticular layer thickness, eosinophils and CD8+ at baseline. Right panel: associations of annual
change (year 2 to 71⁄2) in post-bronchodilator FEV1 with reticular layer thickness, eosinophils and
CD8+ at t=2 years.
baseline year 2
repeating the analysis using the bronchial biopsies taken at 2 years these findings were
entirely confirmed. There was a consistent, significant correlation of annual fall in post-
bronchodilator FEV1 with the number of CD8+ cells at t=2 years (r=-0.39;p=0.036), but
not with bronchial eosinophils or reticular layer thickness [figure 2]. All other cell types
(AA1, CD3 and CD4) demonstrated no significant associations with the annual change in
FEV1 (r<-0.20;p>0.28).
Discussion
The results of this study show that the number of CD8+ cells in bronchial biopsies in
patients with asthma is associated with disease outcome, as determined by loss of lung
function. Other markers of inflammation or remodeling were not related to the decline
in lung function during follow-up. Furthermore, the loss in post-bronchodilator FEV1
was significantly larger than the decline in pre-bronchodilator FEV1. These findings
indicate that CD8 cells can be predictive of disease outcome in asthma and therefore
suggest that targeting specific elements of inflammation may be required when aiming to
prevent the accelerated decline in lung function in patients with asthma.To our
knowledge, this is the first longitudinal study showing the prognostic significance of type
and severity of inflammation on the outcome of asthma. A cross-sectional relationship
between CD8+ cells and the outcome of asthma has been observed in patients with fatal
asthma (22). Recently, increased cytokine production of sputum CD8+ cells has been
shown in patients with asthma that was related with disease severity (23). Interestingly,
the association between lung function and CD8 cells has also been demonstrated in
other diseases: not only by cross-sectional analysis in COPD patients (13), but also
regarding decline in lung function in patients with systemic sclerosis (24). This shows
that our longitudinal findings in asthma are in line with those in other inflammatory
lung disorders.
The magnitude of the annual decline in lung function is in keeping with other
longitudinal studies in patients with asthma and is higher as compared to the figures
previously published for normals (normals: 22 ml/year and asthma: 38 ml/year) (5).
Our results extent previous findings by demonstrating that the decline in post-
bronchodilator FEV1 is larger than the decline in pre-bronchodilator FEV1. This puts
emphasis on measuring post-bronchodilator FEV1, as a ceiling of lung function, in
prospective studies in asthma. 
The present study design may have potential limitations. During the follow-up period of
71⁄2 years, the patients were treated by their own physician as opposed to controlled
standardized therapy. This may have introduced variability in asthma control, since some
patients were seeing a chest physician regularly (22% of patients), whereas others had
not been visiting their doctor for asthma symptoms at all (6% of patients). We consider
this strategy to be representative for the daily practice. Prior to the baseline
bronchoscopy the patients were also treated by their own physician, or were newly
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diagnosed (23% of patients). Moreover, any variability in therapy may have led to a
broader disease outcome, which is likely to be represented by the large range in annual
decline in FEV1. For that reason, we chose common asthma management as opposed to
protocolized therapy during follow-up of this cohort.
It is unlikely that the present association between decline in FEV1 and CD8+ cells, is due
to chance. It was a consistent finding when using bronchial biopsies of two separate
bronchoscopies two years apart. The first and second bronchoscopy differed in such way
that the second biopsy was taken following 2 years optimal treatment according to the
GINA guideline or management additionally based on airway hyperresponsiveness (18).
This suggests that treatment level is not affecting the association between airway
inflammation and lung function decline in asthma.
How can CD8 cells contribute to the accelerated, irreversible airway obstruction in
asthma? In vitro studies have characterized CD8+ cells in regard to their cytokine
production (Tc1 vs Tc2) and populations (effector vs memory) (25). Interestingly, a
subset of antigen specific “non-lymphoid” memory CD8 T cell population, which can be
isolated from several organs including the lungs, demonstrate a high lyctic activity and
proliferate rapidly (26). Various antigens, like allergens and viruses can rapidly activate
specific effector/memory T cells (27). In mice models, CD8 cells are required for the
development of airway hyperresponsiveness following allergic sensitization (28) leading
to increased inflammation (29). During respiratory virus infections, CD8 cells appear to
be essential for the influx of eosinophils into the lung and the development of airway
hyperresponsiveness in mouse models (30). Indeed, we have recently demonstrated that
rhinovirus infection in asthmatic subjects is associated with accumulation of CD8 cells
(31). Interestingly, antigen specific CD8 cells can persist in the lung for several months
(32) and may also activate resident cells such as epithelial cells (33). Therefore, CD8
cells can induce potential conditions that are required for changes in airway structure,
which eventually may lead to changes in airway structure. However, we cannot exclude
the possibility that the association of CD8 cells with lung function decline is just an
epiphenomenon and a marker of a complex immunopathologic pathway.
Eosinophils were not predictive for the decline in lung function in our study. Increased
numbers of sputum and tissue eosinophils have been associated with persistent airway
obstruction in patients with severe asthma (8;15). However, these conclusions were
derived from cross-sectional data. Interestingly, it has been shown that elevated sputum
eosinophil numbers may predict the short-term worsening of asthma as reflected by
exacerbations (34). This suggests that the inflammatory profile may have distinct effects
on short- and long-term disease outcome.
Remarkably, the thickness of the sub-epithelial reticular layer was not related to lung
function decline either. This probably illustrates that restructuring of the airways as
measured in large airway biopsies is not sufficient to represent other aspects of (small)







recently did show an association between airway structure and lung function level (36).
However, comparable data in asthma will not be readily available.
Our findings can have implications for clinical management and drug development.
First, the consistent association between FEV1 decline and CD8 cells even after 2 years of
optimal standardized therapy in our study suggests that the current treatment strategies
for asthma may not be effective in preventing or reversing the accelerated fall in lung
function in patients with asthma. Second, even though the CD8 cell may just be a marker
of another causative mechanism, the possibility to manipulate the presence and/or
phenotype of CD8 cells should be considered. Glucocorticoids are able to induce a CD8
cell phenotype that is producing high levels of IL-10 and reduced levels of IL-4 and IL-5
(37). However, the effect of glucocorticoids modulation of CD8 cell cytokine production
is much smaller as compared to CD4 cells (37). Therefore, the development of new
interventions, specifically targeting CD8+ T cells, may need to be explored when aiming
to prevent the persistent airway obstruction in asthma. 
In conclusion, we have shown that outcome of asthma, as determined by the annual
decline in FEV1, can be predicted by bronchial CD8 cell infiltrate. CD8+ cells may have,
as previously suggested in patients with COPD, a significant role in the clinical course of
asthma. We could speculate that this requires phenotype-specific therapeutic strategies in
order to prevent the accelerated decline of lung function in asthma.
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Abstract
Background: In the current GINA guidelines, the assessment of asthma control is based
on symptoms and lung function. We investigated the value of including PEF-variability in
addition to symptoms and ß2-agonist use, in predicting the development of poor asthma
control in a prospective study.
Methods: 75 patients with asthma had GINA step determined and treatment adjusted at
baseline and after 3 months of follow-up. Data were analysed to ascertain the extent to
which each clinical feature was involved as decisive factors in determining the GINA
grade. Logistic regression analysis was applied to determine the value of PEF-variability
in predicting asthma control at the second visit in the whole group and in a sub-group of
patients with GINA grade 1 and 2 at entry. The optimal cut-off value for loss of control
was determined by the receiver operating characteristic (ROC) curve.
Results: A PEF-variability of 20% determined in 0% of cases the GINA step at baseline.
However, as a continuous variable, PEF-variability provided additional information on
top of symptoms and ß2-agonist use in predicting loss of control (total group: OR=1.14;
p=0.003 and sub-group: OR=1.37; p=0.012). Patients in GINA step 1-2 with PEF-variability
>10% at visit one had a RR of 7.7 (p=0.034) for an increase towards GINA step 3-4 at
follow-up as compared to patients with PEF-variability 10%.
Conclusions: PEF-variability provides useful information in addition to symptoms and ß2-




The current Global Initiative for Asthma (GINA) guidelines for the treatment of asthma
recommend the assessment of symptoms and lung function for successful management
of asthma (1). Since their first publication in 1993, the GINA guidelines have taken a
stepwise standardized approach to asthma treatment, with the treatment level based on
four grades or steps which are determined by clinical features such as daytime and night-
time symptoms and PEF-variability (Figure 1A). The presence of one of the features of a
GINA step is sufficient to place a patient in that category; thus, the GINA step is
determined by the worst among the patient’s clinical features. The cut-off values between
the GINA steps are not evidence-based, but are derived from presumed clinical
significance as assessed by an expert panel through consensus (1). In the 2002 GINA
guidelines, a separate table was added for ongoing assessment of control during
treatment. This table (Figure 1B) utilised a similar categorisation of symptoms and lung







Figure 5-6. Classification of Asthma Severity by Clinical Features Before Treatment
STEP 1: Intermittent
Symptoms less than once a week
Brief exacerbations
Nocturnal symptoms not more than twice a month
● FEV1 or PEF 80% predicted
● PEF or FEV1 variability <20%
STEP 2: Mild Persistent
Symptoms more than once a week but less than once a day
Exacerbations may affect activity and sleep
Nocturnal symptoms more than twice a month
● FEV1 of PEF 80% predicted
● PEF or FEV1 variability 20-30%
STEP 3: Moderate Persistent
Symptoms daily
Exacerbations may affect activity and sleep
Nocturnal symptoms more than once a week
Daily use of inhaled short-acting ß2-agonist
● FEV1 or PEF 60-80% predicted
● PEF or FEV1 variability >30%
STEP 4: Severe Persistent
Symptoms daily
Frequent exacerbations
Frequent nocturnal asthma symptoms
Limitation of physical activities
● FEV1 or PEF 60% predicted
● PEF or FEV1 variability >30%
Figure 1A
features were now considered to reflect the level of control which had been achieved
with treatment (1;2). It can be seen from this approach that the underlying asthma
severity is perceived as driving the appropriate maintenance treatment in order to
achieve control of asthma. Indeed, a prospective evaluation showed that acute health
care utilisation was predicted by an index of asthma control (3).
There is some controversy over whether the assessment of asthma control should include
PEF measurements, at least partly because of difficulty in achieving good adherence with
monitoring. In clinical practice guidelines, the rationale for including both symptoms
and lung function in the classification of asthma control in individual patients has been
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Figure 5-7. Classification of Asthma Severity by Daily Medication Regimen and Response to
Treatment
Current Treatment Step
Step 1: Step 2: Step 3:
Intermittent Mild Moderate
Persistent Persistent
Patients Symptoms and Lung Function on Level of Severity
Current Therapy
Step 1: Intermittent
Symptoms less than once a week Mild Moderate
Brief exacerbations Intermittent
Nocturnal symptoms not more than twice a Persistent Persistent
month
Normal lung function between episodes
Step 2: Mild Persistent
Symptoms more than once a week but less Mild Moderate Severe
than once a day
Nocturnal symptoms more than twice a month Persistent Persistent Persistent
but less than once a week
Normal lug function between episodes
Step 3: Moderate Persistent
Exacerbations may affect activity and sleep
Nocturnal symptoms at least once a week Moderate Several Severe
60% < FEV1 < 80% predicted OR Persistent Persistent Persistent
60% < PEF < 80% personal best
Symptoms daily
Step 4: Several Persistent
Symptoms daily
Frequent exacerbations Severe Severe Severe
Frequent nocturnal asthma symptoms Persistent Persistent Persistent
FEV1 60% predicted OR
PEF 60% of personal best
Figure 1B
Figure 1. Classification of asthma severity in GINA guidelines (A) before treatment and (B) during
treatment (1).
that both symptoms and airway obstruction are integral to the definition of asthma, and
there is a wide variation in the way individual patients manifest inadequacy of asthma
control (4). Monitoring of peak expiratory flow (PEF) has been recommended to
overcome poor perception or under-reporting of symptoms by patients. Furthermore, it
has been found that successful control of both symptoms and peak expiratory flow (PEF)
leads to improvements in quality of life which therefore benefits the patient (5). 
Peak flow measurements may be summarised in several different ways, including the 
PEF-level (clinic PEF measured by the clinician, or, alternatively, mean daily PEF,
expressed as a percentage of predicted or of personal best) and PEF-variability
(amplitude as percentage of mean value). In the 2002 GINA guidelines, there is an
unexplained distinction between the initial assessment, when both PEF-variability and
PEF-level are used (Figure 1A), and the ongoing assessment during treatment, when
PEF-level alone is used (Figure 1B) (1).
To date, there are few data on the relative contribution of symptoms and PEF to the
classification of asthma control and the resulting maintenance treatment according to
GINA guidelines in clinical practice. We assessed the extent to which different levels of
PEF-variability provide information on asthma control in addition to that provided by
symptoms and ß2-agonist use. Furthermore, we evaluated the value of including PEF-
variability in addition to symptoms and ß2-agonist use in predicting the development of
poor asthma control in a prospective study.
Methods
Subjects
Seventy-five atopic patients with mild to moderate persistent asthma, who participated in
the 2-years prospective AMPUL (Asthma Management Project University Leiden) study,
were included in the analysis (6). All patients had a history of episodic chest tightness or
wheezing and prior to entry were treated with or without inhaled steroids. They were 18-
50 years and non- or ex-smokers (>1 yr; <5 packyrs). The pre-bronchodilator forced
expiratory volume in one second (FEV1) was more than 50% of predicted, whilst post-
bronchodilator FEV1 was within the normal range (>80% predicted). All were
hyperresponsive to methacholine (PC20 < 8 mg/ml) (6).
The medical ethics committee of the Leiden University Medical Center approved the
study and all participants gave written informed consent.
Design
In the prospective study, treatment was adjusted every 3 months for 2 years in a referral
hospital according to the GINA guidelines. Full details of the methodology have
previously been published (6). For the present analysis, the first 2 visits (i.e. baseline visit,
at which the first treatment adjustment was made, and the first follow-up visit, 3 months
later) were used.
Before each visit, patients kept a diary card for 2 weeks on which day- and night-time







recorded twice daily on a 0-4 scale (6), and the scores were converted to a categorical
scale equivalent to that in the GINA guidelines. AM and PM peak flows were used to
calculate PEF-variability (amplitude%mean) (1), using the PEF cutpoints specified in the
GINA guidelines (7). As recommended in the guidelines, the worst feature was used to
determine the GINA step and hence the level of treatment for the first 3 months.
Twenty-three patients had newly detected asthma and were classified according to Figure
1A of the guidelines, whilst the other 52 patients were on regular inhaled steroids and
were therefore classified according to Figure 1B.
Analysis
We analysed data from the first visit to ascertain the extent to which each clinical feature
was involved as (one of) the decisive factors in determining the GINA grade. The clinical
features which are accessible to a general practitioner (day and night-time symptoms,
bronchodilator use and PEF variability) were included in the analysis. Second, logistic
regression analysis was applied to determine the value of PEF-variability as a continuous
variable, in addition to symptoms, in predicting asthma control at the second visit
(dependent variable: GINA grade 1 and 2 versus GINA grade 3 and 4 at visit two;
independent variables: GINA grade and PEF variability at visit one). A sub-group analysis
was performed for the patients in GINA grade 1 and 2 at visit one. Only these patients
might be classified in a higher GINA grade based on their PEF-variability, whereas for the
patients in GINA grade 3 and 4, adding PEF variability could not change their
classification, since symptoms and or bronchodilator use had already placed them in a
higher GINA grade. Next, based on a receiver operating characteristic (ROC) curve, an
optimal cut-off value for PEF variability was selected for prediction of loss of control
(GINA step 1 and 2 versus GINA step 3 and 4) at the second visit. Finally, logistic
regression analysis was carried out to determine the risk of patients in GINA grade 1 and
2 with a PEF-variability higher than the selected cut-off value to be classified in GINA
grade 3 or 4 at the second visit.
P-values of less than 0.05 were considered as significant and STATA was used to analyse
the data.
Results
Contribution of clinical features to GINA grade
At Visit 1, the distribution of patients among the GINA steps was Step 1 17%, Step 
2 28%, Step 3 35% and Step 4 20%. The GINA grade was determined by one single
factor in 82.1% of the patients. Figure 2 shows the percentage of patients in whom a
particular clinical feature was involved as (one of) the determining feature(s) to 
allocate an individual patient to GINA step 2 or higher. Symptom was by far the most
dominant feature in determining the GINA level and thereby the level of asthma
treatment (figure 2, top panel). For no patient (0%) was the level of control determined
by PEF-variability, using the cut-off value of 20% which is specified in the GINA
guidelines.
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Prognostic value of PEF-variability
Logistic regression analysis showed that at the first visit, PEF-variability significantly
provided additive information on top of symptoms in predicting the level of asthma
control (GINA grade 1 and 2 versus GINA grade 3 and 4) at the second visit (RR=1.14;
p=0.003).
Sub-group analysis
A logistic regression, analysing the additional value of PEF-variability in determining
asthma control, was repeated in the sub-group of 40 patients categorised in grade 1 and
2 at the first visit. In this sub-group, again PEF-variability on top of symptoms significantly
predicted asthma control at the second visit (RR=1.37; p=0.012).
The area under the curve (AUC) of the ROC curve for using PEF-variability on top of
the current guidelines for predicting asthma control at the second visit was 0.75. From
this ROC curve (Figure 3) a cut-off value of PEF-variability >10% was selected based on







Figure 2. Percentage of visits on which a particular clinical feature was involved as 
(one of) the driving features to allocate a patient in GINA severity grade 2 or higher. Two different
cut-off value for PEF-variability were used in the analysis: when using 
PEF-variability < 20% (top panel) and when using PEF-variability < 10% (bottom 
panel).
PEF variability 20% cut-off























Applying cut-off value of PEF-variability >10%
The cut-off value of PEF variability 10% gave a sensitivity of 36%, a specificity of 93% and
a likelihood ratio (LR) for a positive result of 5.27.
Logistic regression analysis showed that patients in GINA control step 1 or 2 with PEF
variability >10% at baseline had an OR of 7.71 (p=0.034) for an increase in GINA level at
the second visit as compared to patients with PEF variability 10%.
A retrospective re-classification of GINA categorisation at baseline was performed using
PEF-variability with the proposed cut-off value of >10%, instead of the existing cutpoint
of 20%. With this cutpoint, PEF-variability would have determined the GINA step at
baseline in 10.2% of the patients [figure 2, bottom panel].
Discussion
Our results have shown that PEF variability provides information about asthma control in
addition to symptoms and ß2-agonist use. Furthermore, this study demonstrated that
patients who were classified as being in GINA step 1 and 2 using the existing GINA
criteria, but who had PEF-variability >10% had an almost 8 times higher risk for loss of
asthma control 3 months later compared to patients whose PEF-variability was 10% at
baseline. This suggests that including PEF-variability in the assessment of asthma control
during treatment can improve the current guidelines for the treatment of asthma, but
that the existing cut-points for PEF-variability are too high.
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Figure 3. ROC curve
for using PEF-
variability on top of the
current guidelines for
predicting asthma
severity (GINA grade 1
and 2 versus GINA
grade 3 and 4) at the
second visit. The area
under the curve was
0.75.
This is the first study showing the additional value of measuring PEF-variability in the
management of asthma. These results extend previous findings which showed that PEF-
variability in selected populations is valuable for epidemiological and diagnostic
purposes (8-10). We have demonstrated that when using a cut-off value of 10%, PEF-
variability is able to identify patients with an increased risk of loss of control of asthma.
Previous studies have shown that patients with poor asthma control demonstrate higher
PEF-variability compared to stable asthmatics (11). Furthermore, our findings are
consistent with results from Nathan et al. who showed that a 10% cut-off value for PEF
variability identifies patients with greater benefit from treatment (12).
We believe that our results have not been affected by patient selection or the methods of
asthma monitoring. The current group of asthmatics seems to be representative of a
broad range of asthma severity, since our patients were equally distributed over the 4
GINA grades. We cannot exclude that a patient group with a different balance of asthma
severity would lead to different results. However, all our measurements were strictly
based on asthma guidelines, allowing extrapolation of our findings to asthma care
elsewhere.
The 10% cut-off value of PEF-variability was selected based on the high specificity and
likelihood ratio observed. Even though we have shown that this cutpoint identifies
patients at greater risk of loss of control, the most optimal cut-off value has to be
investigated in large follow-up studies. 
The cut-off value of PEF variability of 10% is in contrast with the 20% cut-off used in the
current GINA guidelines. The number of PEF readings per day could readily explain this
lower value. Indeed, reducing the frequency of measurements has been shown to
underestimate the diurnal variation in PEF (13,14). The cut-off value of 20% stated in
the present guidelines was based on studies where PEF was determined more frequently
(18), whereas when PEF was measured twice daily, as is current practice, the upper 95%
confidence limit for normal PEF-variability was 8-9% (15;16). Indeed in our study, in
which PEF was measured twice daily, the PEF-variability was below the conventional cut-
off value of 20% in almost all patients and therefore never determined the level of
treatment, although these patients by other criteria had sub-optimally controlled asthma.
How can these results be interpreted? Airway hyperresponsiveness is an important
characteristic of asthma (1). Previously, we have shown that asthma treatment aimed at
reducing airway hyperresponsiveness is more effective in gaining control than therapy
adjustment based on symptoms and level of lung function alone (6). Diurnal changes in
PEF have been suggested as an indicator of the responsiveness observed in asthma (17).
In this respect, the additional value of PEF-variability in asthma management observed in
our study is not surprising. In addition, PEF-variability appears to be associated with
eosinophilic inflammation in sputum in patients with asthma (18). Again, a strategy that
minimises eosinophilic inflammation leads to improved asthma management as
compared with a standard strategy (19). This implies that a feature reflecting airway







of asthma management to optimise control of the disease. PEF-variability might be an
appropriate indirect marker for this, which is accessible even in primary care settings
where bronchial provocation testing or sputum induction are not readily available. 
In conclusion, PEF-variability with a cut-off level of 10% provides additional information
to monitor asthma control in addition to symptoms and lung function. Our data suggest
that determining PEF-variability is not only useful for the diagnosis of asthma, but is also
valuable for adjusting therapy of patients during treatment to thereby prevent loss of
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Abstract
Background Anti-IgE, omalizumab, has been shown to inhibit the allergen response in
patients with asthma. This has not been directly related to changes in inflammation.
Objective We hypothesised that anti-IgE exerts its effects by reducing airway
inflammation. To that end, the effect of anti-IgE on allergen-induced inflammation in
bronchial biopsies in 25 patients with asthma was investigated in a randomised, double
blind, placebo-controlled study.
Methods Allergen challenge followed by a bronchoscopy at 24h was performed at
baseline and after 12 weeks of treatment with subcutaneous anti-IgE or placebo. PC20
methacholine and induced sputum was performed at baseline, 8 and 12 weeks of
treatment. Changes in the early and late responses to allergen, PC20, inflammatory cells
in biopsies and sputum were compared between anti-IgE and placebo.
Results Both the early and late asthmatic response were suppressed to 15.3% and 4.7%
following anti-IgE as compared with placebo (p<0.002). This was paralleled by a decrease
in eosinophil counts in sputum (from 4% to 0.5%) and post-allergen biopsies (from 15
to 2 cells/0.1mm2) (p<0.03). Furthermore, biopsy IgE+ cells were significantly reduced
between both groups, whereas high-affinity IgE receptor and CD4+ cells were decreased
within the anti-IgE group. There were no significant differences for PC20 methacholine 
Conclusion The response to inhaled allergen in asthma is diminished by anti-IgE, which
is paralleled by a reduction in eosinophilic inflammation in bronchial mucosa and
sputum and a decline in bronchial IgE positive cell counts post-allergen without
changing PC20 methacholine. This suggests that the benefits of anti-IgE in asthma may
be explained by a decrease in eosinophilic inflammation and IgE bearing cells.
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Introduction
Thirty years after it was first identified, there is substantial evidence that immunoglobulin
E (IgE) plays a key role in allergic asthma (1). In a population-based study, Burrows et al.
were the first to show a strong association between serum IgE levels and self-reported
asthma (2). Furthermore, high levels of circulating IgE have been shown to correlate
with the risk of emergency room admissions in patients with asthma (3). IgE induces
mediator release of mast cells and basophils via binding to high-affinity receptors, and
thereby leads to activation of immune responses (4). Taken together, this makes
immunomodulation of IgE an interesting strategy for new therapeutic interventions in
asthma (5).
A recombinant, humanized, monoclonal antibody directed against IgE has been
developed. This antibody decreases the levels of circulating IgE by binding to the
constant region of the IgE molecule, which prevents free IgE from interacting with high-
and low-affinity IgE receptors (FcRI and FcRII) (6). Anti-IgE has been found to
decrease IgE levels and downregulate FcRI expression on basophils and dendritic cells
in blood (7;8).
The first clinical studies with intravenous anti-IgE have shown that both the early (EAR)
and late (LAR) asthmatic response to inhaled allergen are attenuated in patients with
asthma (9;10). Subsequent large phase 3 trials, involving both pediatric and adult
patients with moderate to severe asthma, have demonstrated the clinical beneficial effect
of subcutaneous anti-IgE treatment by improving asthma control (11-13). A recent
double-blind, placebo-controlled study confirmed the effectiveness of anti-IgE treatment
in inadequately controlled severe persistent asthma by showing a reduction in
exacerbation rate and emergency room visits and an improvement in quality of life and
morning peak flow (14).
The anti-inflammatory activity of anti-IgE was established in a biopsy study of mild
asthmatic patients (15). Following 16 weeks treatment with anti-IgE significant
reductions in IgE positive cells and eosinophils in the bronchial mucosa were found
(15). It remains unclear whether the inhibition of the allergen response by anti-IgE
treatment can be explained by a reduced airway inflammation.
The aim of the present study was to determine whether treatment with anti-IgE decreases
the early and late responses to inhaled allergen and whether this is associated with a
reduced allergen-induced airway inflammation in bronchial biopsies. Furthermore, the
effect of anti-IgE on peak flow, airway hyperresponsiveness and inflammatory cells in










Twenty-five non-smoking asthmatic volunteers (18-29 years) participated in the study
[Table 1]. All patients had a history of episodic chest tightness and wheezing and were
only using short-acting ß2-agonists on demand. All were atopic to house dust mite
(HDM) and were having a total serum IgE between 30 and 700 IU/ml. The baseline
forced expiratory volume (FEV1) was > 70% predicted (16) and all subjects were
hyperresponsive to inhaled methacholine (provocative concentration causing a 20% fall
in FEV1 (PC20) <4 mg/ml) (17). The fall in FEV1 during the late asthmatic response
(LAR) following inhaled allergen was at least 15%. All patients were clinically stable and
had no respiratory chest infection 2 weeks prior to the study. The study was approved by
the medical ethics committee of the Leiden University Medical Center and all volunteers
gave a written informed consent.
Design
This study had a randomized, placebo-controlled, parallel, double-blind design. Anti-IgE
or placebo was administered for 12 weeks every 2 or 4 weeks. At baseline, after 8 and 12
weeks of treatment, PC20 methacholine was determined and sputum induced. Allergen
challenge followed by a bronchoscopy at 24 hours was performed at baseline and 12
weeks.
Treatment
The dose (150 mg to 375 mg) and frequency (every 2 or 4 weeks) of treatment was
determined by weight and baseline total serum IgE level of each patient and had to be 
al least 0.016 mg/kg per IgE (IU/ml) (18). A research nurse who was not involved in 
any other measurement of the study administered the subcutaneous anti-IgE or 
placebo.
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Table 1. Patient characteristics
characteristic anti-IgE (n=12) placebo (n=13)
age (years) 20.5 (18-24) 21 (19-29)
female sex, n (%) 12 (100) 10 (77)
smoking history, n (%)
never 11 (92) 12 (92)
ex-smoker 1 (8) 1 (8)
duration of asthma (years) 10.5 (1-19) 9.0 (4-22)
total IgE (IU/ml) 154 (51-674) 321 (35-593)
FEV1 (%pred) 96.0 (82-115) 88.8 (72-114)
PC20 methacholine (mg/ml)* 0.48 (1.61) 1.02 (1.93)
Data are presented as median (range); * g-mean (SD in dd);
There were no significant differences between the groups.
Diary cards
Patients kept diary cards from 2 weeks prior to and during the 12 weeks of the study.
Morning and evening pre-bronchodilator peak flow measurements were recorded. Mean
PEF values of the 2 weeks prior to baseline measurements of the study and the mean PEF
values of the 2 weeks prior to the 12 week-measurements of the study were used in the
analysis.
Spirometry and Airway hyperresponsiveness
Patients were not allowed to take any short-acting ß2-agonists for at least 8 hours prior to
spirometry. A standardized methacholine challenge was applied to determine airway
hyperresponsiveness (17). To determine the PC20 methacholine, patients inhaled
increasing doses of methacholine for 2 minutes until a fall of at least 20% in FEV1 had
been reached.
Sputum induction and processing
Prior to induction, each subject inhaled 200 µg salbutamol. Sputum was induced by
inhalation of NaCl 4.5% during 3x5 minutes intervals, according to a recommended
protocol validated in our laboratory (19;20).
Sputum samples were processed according to the whole sample method. Differential cell
counts were expressed as a percentage of 250 non-squamous cells (20).
Allergen challenge
Allergen challenges were performed according to a standardized protocol (17;21).
Purified aqueous allergen extract of Dermatophagoides pteronyssinus (SQ 503; Vivodiagnost,
ALK, Benelux), with 0.5% phenol as a preservative, was diluted ranging from 2,000-15.63
BU/ml. PC20 allergen was predicted from PC20 methacholine and skin-test sensitivity,
derived from a multi-dose skin prick test, according to Cockcroft’s method (21). Starting
three concentrations below the predicted PC20 allergen, 3 ml of consecutive doubling
concentrations of allergen were aerosolized for 2 minutes using a DeVilbiss 646
nebulizer (output 0.13 ml/min). The response to allergen was determined by measuring
FEV1 in duplicate 10 min after each inhalation of allergen. After reaching a fall of at least
20%, FEV1 measurements were repeated 10, 20, 30, 40, 50, 60, 90, and 120 minutes and
then hourly until 7 hours after the last inhalation. In the analysis, EAR (from 0-3 hours
post-allergen) and LAR (from 3 to 7 hours post-allergen) were defined as the maximum
% fall in FEV1 from baseline and as the area under the time-response curve (AUC) (17).
Patients received exactly the same allergen dose at the end of the study as they inhaled
during the baseline allergen challenge.
Bronchoscopy and immunohistochemistry
Fiberoptic bronchoscopy was performed according to a standardized and validated
protocol (22). Six biopsy specimens were taken at (sub)segmental level from either the
right lung (first bronchoscopy; right lower lobe and/or the middle lobe) or the left lung
(second bronchoscopy; lingula and left lower lobe). Two biopsies were immediately







The remaining 4 biopsies were fixed for 24 hrs in buffered formalin and paraffin
embedded. Three µm thick, HE stained slides were used for checking biopsies quality (size,
crushing, epithelial and mucosal representation) and the two technically best biopsies were
selected for immonuhistochemistry. Slides were immunostained for IgE, high and low
affinity IgE receptor (FcRI and FcRII), eosinophils (EG2), mast cells (AA1), neutrophil
elastase (NE), macrophages (CD68), and T lymphocytes CD3, CD4, and CD8. In short, the
sections were incubated with an optimal dilution of the primary antibodies in 1%
BSA/PBS at room temperature for 60 min. As a secondary antibody, the horseradish
peroxidase conjugated anti-mouse or anti-rabbit EnVision system (DAKO, Glostrup,
Denmark) was used, with NovaRED (Vector, Burlingame, CA) as the chromagen. The
sections were counterstained with Mayer’s hematoxylin (Klinipath, Duiven, the
Netherlands). For negative controls, the first antibody was omitted from this procedure.
All biopsies were coded and sections analysed in a blinded fashion, using a fully
automated image analysis system (23). Images were digitized using a three-chip colour
camera (433.103 pixels, 660x496µm2, 3x256 grey values) (KS-400 System, Kotron/Zeiss).
The whole available area of lamina propria was determined by manually delineating the
basement membrane. Lamina propria was defined by the widest possible 125 µm deep
zone beneath the basement membrane of at least 86,000 µm2. The automated counting
of the number of positively staining cells consisted of the following steps: level off
background noise, normalize staining intensity, delete noise, fuse stained fragment,
delineate stained clusters, determine cell counting by an algorithm. This method has
been shown to be fully reproducible and to have good agreement with interactive cell
counting (23). Data were expressed as cells/0.1mm2.
Analysis
The PC20 methacholine, cell counts in sputum and biopsies were log transformed before
statistical analysis. All data are presented as median (range), except for PC20
methacholine which is presented as geometric mean (SD expressed as doubling dose).
Paired t-test was applied to test for changes within groups, whereas unpaired t-test was
used for changes from baseline to end between anti-IgE and placebo treatment groups. A
p-value of < 0.05 was considered as statistical significance and all analyses were
performed using SPSS 12.0.
Results
From one patient in the placebo group, no biopsies were obtained during the second
bronchoscopy. Consequently, a total of 24 patients completed the study (anti-IgE: n=12;
placebo: n=12). Three patients in the anti-IgE group and 4 patients in the placebo group
did not produce sputum at one of the time points. Matched sputum samples were
therefore obtained from 18 patients (anti-IgE: n=9; placebo: n=9).
Baseline FEV1 was 96.3% predicted in anti-IgE group and 90.8% predicted in the
placebo group. There were no significant changes for FEV1 within or between groups
during the study (p>0.07). 
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Diary cards
Morning PEF was significantly increased from 383.6 L/min (314.6-469.2) at baseline to
430.0 L/min (325.8-503.3) after 12 weeks of anti-IgE (p=0.038). This increase was
significantly different from the change in the placebo group (398.5 L/min (342.1-613.8)
to 392.1 L/min (349.3-608.5) (p=0.53 for the change within the placebo group)
(p=0.041 for the change from baseline between anti-IgE and placebo groups). Similar








Individual values of morning (top
panel) and evening (bottom panel)
PEF at baseline and end of the study
in anti-IgE and placebo treated
patients.
Allergen Challenge
At baseline, the maximum % fall in FEV1 during the EAR was (median (range)) 28.9%
(19.4-38.6) for the anti-IgE group and 27.0% (20.3-35.9) for placebo. Anti-IgE treatment
significantly inhibited the EAR to 15.3% (0.0-23.8) (p=0.000). This change was
significantly larger as the change in the placebo group (p=0.002). The AUC of the EAR
was also significantly reduced following anti-IgE treatment (28.0 percentage fall per hour
(%fall*h) (2.7-49.3) to 15.3 %fall*h (0.0-23.8)) as compared to placebo (33.5 %fall*h
(14.2-41.9) to 23.2 %fall*h (6.0-37.1) (p=0.002) [Figure 2].
The maximum % fall during the LAR was suppressed following anti-IgE treatment from
36.1% (18.9-52.7) to 4.7% (0.0-20.6). This reduction was significantly larger as compared
with placebo (31.1% (12.8-54.0) to 25.4% (14.0-48.2)) (p=0.000 for the change from
baseline between anti-IgE and placebo). In addition, the reduction in AUC of the LAR
was significantly larger in the anti-IgE group (95.6 %fall*h (13.9-182.9) to 9.3 %fall*h 
(-23.0-52.8) as compared with the placebo group (89.9 %fall*h (12.4-152.2) to 56.0






between 0 to 7 hours
following allergen
challenge for the anti-
IgE group (top panel)
and for the placebo
group (bottom panel).
In the anti-IgE group,
EAR and LAR were
significantly reduced
from baseline (open
circles) to end (closed




Anti-IgE treatment markedly reduced the submucosal IgE+ cells from 15.8 cell/0.1mm2
(3.0-42.0) to 0.0 (0.0-19.0) (p=0.000). This reduction was significantly larger as compared
with the placebo group (35.5 cell/0.1mm2 (3.0-54.5) to 30.3 (2.5-63.0) (p=0.000 for
changes from baseline between anti-IgE and placebo) [Figure 3]. FcRI+ cells were also
significantly reduced within the anti-IgE group (p=0.013). However this change was not
significantly different from the change in the placebo group (p=0.49 for the change
from baseline between anti-IgE and placebo) [Figure 3]. Most biopsy samples did not







Figure 3. Biopsy IgE+ and FcRI+
cells
Individual values of IgE+ (top panel)
and FcRI+ cells (bottom panel) at
baseline and end of the study in anti-
IgE and placebo treated patients.
There was a clear reduction in eosinophil counts in the anti-IgE group (15.0
cells/0.1mm2 (1.0-48.5) to 2.0 cells/0.1mm2 (0.5-3.0) ) (p=0.000), which was significantly
different from the placebo group (14.5 cells/0.1mm2 (1.0-118.5) to 11.0 cells/0.1mm2
(1.5-77.0) (p=0.005 for the change from baseline between anti-IgE and placebo) [Figure
4].
There were no significantly differences between anti-IgE and placebo observed for mast
cells, macrophages, neutrophil elastase and B-lymphocytes (p>0.09). CD4+ T-
lymphocytes were significantly reduced after anti-IgE treatment (p=0.021), however,
there were no significant between-group differences for the T-lymphocytes (p>0.14).
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Figure 4. Biopsy eosinophils
Individual values of eosinophils at
baseline and end of the study in






baseline, to 8 weeks and





The median (range) % sputum eosinophil decreased in the anti-IgE treated group from
4.0% (0.2–28.0) at baseline, to 0.8% (0.2-10.8) after 8 weeks and to 0.5% (0.0-1.6) at the
end of the study (after 12 weeks of treatment). This change was significantly different
with placebo (baseline: 2.2% (0.4-10.2); 8 weeks: 1.0% (0.2-10.8); 12 weeks: 2.6% (0.4-
13.8) after 12 weeks of treatment (p=0.03 for the change from baseline between anti-IgE
and placebo) [Figure 5].
None of the other cell types in induced sputum showed any significant changes.
Airway hyperresponsiveness
PC20 methacholine was measured (geometric mean (SD expressed as doubling dose)
0.48 (1.61) at baseline, 0.94 (1.89) after 8 weeks and 1.04 (2.06) after 12 weeks in the
anti-IgE group and 1.02 (1.93), 1.30 (2.16), 1.90 (2.26) in the placebo. There were no
significant differences for the changes between the groups (p>0.18) [Figure 6].
Discussion
The results of this study show that anti-IgE treatment leads to a marked reduction of
eosinophil counts in sputum and biopsies and IgE+ cells in biopsies. This suppression of
inflammation is paralleled by a clear inhibition of both early and late response to inhaled
allergen and a significant improvement in morning and evening PEF rates. However,
PC20 methacholine was not changed by anti-IgE treatment. These findings indicate that
the blunting of the allergen response by anti-IgE may be explained by a decrease in
eosinophilic inflammation and IgE bearing cells. Interestingly, our results suggest that
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To our knowledge, this is the first clinical study with anti-IgE demonstrating that the
effects on allergen-induced airway responses are paralleled by a reduction in airway
inflammation in patients with asthma. Our functional outcomes are in line with others
who showed the inhibitory effect of anti-IgE treatment on early and late asthmatic
response (24;25). Our results indicate that the major anti-inflammatory effects of anti-
IgE are based on a marked fall in eosinophils and local IgE production in the airways.
This extends the effects shown on nasal inflammation in patients with rhinitis and on
airway inflammation in patients with asthma (26;27). Like Djukanovic et al., we have
demonstrated the anti-inflammatory effect of anti-IgE treatment in bronchial biopsies
(26). In contrast with their study, we showed also a clear clinical beneficial effect of anti-
IgE on morning and evening PEF and on response to inhaled allergen (26).
In the present study, airway hyperresponsiveness was not improved following anti-IgE
treatment as compared with placebo. Our results are in keeping with previous studies
also showing no or marginal effects on PC20 methacholine (24-26;28).
We do not believe that our data were influenced by measurement errors, since we 
used validated and reproducible methods (16;17;20;22;23). All subjects in this study 
were carefully selected non-smokers with stable, atopic, mild-intermittent asthma, who
had not used inhaled steroids for at least 1 month prior to the study. In order to
compare the allergen-induced inflammation in the bronchial biopsies, the allergen
challenge at the end of study was performed in a similar manner to the baseline allergen
challenge.
What is the mechanism by which anti-IgE treatment gives such a marked reduction in
eosinophilic inflammation? Via cross-linking with high-affinity receptors on mast cells,
IgE induces the release of preformed mediators, such as histamine and thereafter the
release of newly formed mediators and cytokines such as TNF-, IL-4 and IL-5, leading to
the accumulation of eosinophils (4). Treatment with anti-IgE is likely to intervene in this
mechanism. Indeed, a reduction in cell surface IL-4 following anti-IgE treatment has
been demonstrated (15). A second mechanism, by which anti-IgE affects eosinophils,
might be related to the inhibitory effects of anti-IgE on dendritic cell FcRI expression
(8). It has been proposed that anti-IgE can alter allergen presentation by dendritic cells
(1). Anti-IgE treatment may decrease the uptake and presentation of allergens by
dendritic cells, leading to a reduced T cell response, which may diminish eosinophilic
airway inflammation (29).
Interestingly, we have shown that the effect of anti-IgE is much larger for the late
asthmatic response than for the early response. The EAR is predominantly mediated by
IgE-triggered mast cell mediator release of histamine and tryptase (30). Free IgE is
markedly reduced following anti-IgE treatment, the number of mast cells was not
changed in our study. Apparently, it is not the number of mast cells that is important, but
it is whether they are loaded with IgE. Furthermore, resulting from the minimal amount
of IgE that is probably available after treatment, cross-linking with high-affinity receptors
still might occur and thereby leading to an early asthmatic response.
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Airway hyperresponsiveness is an important feature of patients with asthma (31), but
anti-IgE treatment did not appear to affect it. We cannot exclude that airway
hyperresponsiveness might improve after longer treatment with anti-IgE, since our
patients were only treated for 12 weeks. Results of therapy with anti-IL5, which also
results in an abolishment of eosinophils, have shown no effect on airway
hyperresponsiveness either (32). These findings confirm the dissociation of eosinophils
and airway hyperresponsiveness in asthma as observed in some animal models (33).
Treatment with inhaled steroids, in contrast, reduces both eosinophils and airway
hyperresponsiveness (34). Possibly, inhaled steroids not only affect eosinophilic
inflammation, but also affects the functional properties of airway smooth muscle,
whereas the effects of anti-IgE treatment are mediated through anti-inflammatory
properties alone.
Our findings may have several clinical implications. First, we have shown that PEF,
allergen-induced airway responses and airway inflammation are strongly reduced after
anti-IgE treatment within one study. This implies that indeed anti-IgE exerts its clinical
beneficial effects by reducing airway inflammation and thereby might be an effective
therapy for asthma. On the other hand, anti-IgE treatment had no effect on airway
hyperresponsiveness in our study. We have previously shown that treatment aimed at
reducing airway hyperresponsiveness leads to more effective control and thereby a
reduction of exacerbations in patients with asthma (35). Therefore, the inability of anti-
IgE treatment to normalize airway hyperresponsiveness requires further investigation.
In conclusion, treatment with anti-IgE inhibits both allergen-induced airway response
and airway inflammation in patients with asthma. We have shown that the most
important anti-inflammatory effect of anti-IgE is on reducing eosinophilic inflammation
and IgE-bearing cells. The suggestion that airway hyperresponsiveness appears to be
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Summary and general discussion
Summary
Airway inflammation is the key characteristic of asthma. In this thesis, we have
investigated different aspects of this inflammatory process in patients with asthma. First,
the pathogenesis of the disease was explored in a proof of concept study. Second,
monitoring of airway inflammation was studied by examining markers of airway
inflammation. Third, treatment of airway inflammation was investigated by studying
improvements for asthma management. The main conclusions from these studies are
summarized below.
Proof of concept
In chapter 2, we have shown that exogenous IL-5 is mainly effective in the circulation by
enhancing the number of eosinophils to the circulation. There was no effect on the
number of eosinophils in the lungs or on airway hyperresponsiveness. This suggests that
IL-5 is able to promote the recruitment of eosinophils to the circulation.
Monitoring
The steroid-induced changes in airway hyperresponsiveness, sputum eosinophils and
exhaled NO were compared in chapter 3. Treatment with inhaled steroids leads to
significant improvements in airway hyperresponsiveness, reduced numbers of
eosinophils in sputum, and decreased levels of exhaled nitric oxide in patients with
asthma. The steroid-induced changes for each of the three different markers were not
related. Therefore, the data suggest that these markers may provide different
information when monitoring anti-inflammatory treatment in asthma.
Microvascular leakage is an important feature of inflammation. In chapter 4, an
investigational model of “dual induction” was introduced to determine the level of
microvascular leakage in patients with asthma. Using this model, it was possible to detect
microvascular leakage by first inducing leakage with inhaled substance P and then
measuring leakage in induced sputum. Alpha-2-macroglobulin appeared to be the most
appropriate marker. This implies that this “dual induction” model can be applied when
testing the antiexudative effect of newly developed drugs.
Chapter 5 demonstrated that the outcome of asthma, as determined by the annual
decline in FEV1, can be predicted by the bronchial CD8+ cell infiltrate. On the other
hand, eosinophils in bronchial biopsies and the thickness of the sub-epithelial reticular
layer were not associated with the decline in lung function. This suggests that
inflammatory phenotypes in asthma may have prognostic relevance.
Management
In chapter 6, we have shown that PEF variability provides information about asthma
severity in addition to symptoms and ß2-agonist use. Patients who were classified as being
in severity step 1 and 2 using the existing GINA criteria, but who had PEF-variability
>10% had an almost 8 times higher risk for an increase in asthma severity 3 months later
compared to patients whose PEF-variability was 10% at baseline. Therefore, the current
guidelines for the treatment of asthma can be improved by including PEF-variability in
the assessment of asthma severity during treatment.
Treatment with anti-IgE, omalizumab, has recently been FDA approved for patients with
moderate to severe persistent, IgE-mediated asthma that is sub-optimally controlled with
inhaled steroids. We have demonstrated in chapter 7 that PEF values were improved and
that the response to inhaled allergen in asthma was diminished by anti-IgE. This was
paralleled by a reduction in eosinophilic inflammation in bronchial mucosa and in
induced sputum and a decline in bronchial IgE positive cell counts post-allergen. On the
other hand, anti-IgE treatment did not improve airway hyperresponsiveness in these
patients. This suggests that the clinical benefits of anti-IgE in asthma may be explained
by a decrease in eosinophilic inflammation and IgE bearing cells. Furthermore, airway
hyperresponsiveness appears to be independent of IgE.
General discussion
Proof of concept: is inflammation the right target?
Airway inflammation in asthma is complex in origin, regulation and outcome. There is
still a lack of understanding of the mechanisms involved in asthma (1). Proof of concept
studies may be useful to investigate the underlying pathogenesis of asthma. In this thesis
we have performed a proof of concept study by questioning whether exogenous IL-5
leads to airway inflammation in asthma and whether the route of IL-5 production is
crucial to its effects on the airways. IL-5 plays an important role in the mobilisation,
differentiation and maturation of eosinophils (2). A causal relationship between the key
pathological feature of asthma: eosinophils, and the key physiological characteristic:
airway hyperresponsiveness, has been a long question of debate. The effects of inhaled
steroids are suggestive for a causal relationship, since they both improve eosinophilia
and airway hyperresponiveness in patients with asthma. On the other hand, the steroid-
induced changes between sputum eosinophils and airway hyperresponsiveness were not
related (Chapter 3). Some animal models, investigating the effect of IL-5 on
eosinophilia, have shown the subsequent development of airway hyperresponsiveness,
whereas others have not (3-6). In Chapter 2, we have demonstrated that intravenous
administration of IL-5 to patients with asthma leads to an increased number of
eosinophils in blood, but not in sputum. However, airway hyperresponsiveness was not
affected. On the other hand, Shi et al did show an increase in airway hyperresponsiveness
following IL-5 administration (7). This discrepancy may be related to differences in
racial susceptibility to the effects of IL-5, since these studies were performed in ethnically
different populations. The development of a monoclonal antibody against IL-5 further
challenged the hypothesis that the eosinophil is the central effector cell in asthma (8).
Anti-IL-5 treatment in patients with asthma abolishes eosinophils in blood and sputum,
but this fall in eosinophils was not accompanied by changes in airway







and co-authors have demonstrated that anti-IL-5 treatment only partially depletes the
numbers of eosinophils in bronchial biopsies of patients with asthma (10). Interestingly,
anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial
basement membrane (11). The finding that the response to inhaled allergen is
unaffected by anti-IL5 makes its unlikely that anti-IL5 treatment will be beneficial to
control asthma. The drugs that are effective in asthma control (inhaled steroids,
cromolyn, theophylline, leukotriene antagonists, and anti-IgE) all inhibit the late
response to allergen. Long-acting ß2-agonists also appeared to inhibit the late response
by reducing airway inflammation (12). However, a study showed that long-acting 
ß2-agonists modify allergen-induced airway responses through functional antagonism
rather than the inhibition of inflammatory cell infiltration (13). 
But, is it also true for airway hyperresponsiveness, that all effective asthma drugs improve
airway hyperresponsiveness? Indeed, treatment with inhaled steroids, cromolyn,
theophylline and leukotriene antagonists reduce airway hyperresponsiveness in asthma.
Anti-IgE treatment, however, apparently has no effect on airway hyperresponsiveness
after short-term treatment (Chapter 7) (14). Therefore, it seems that eosinophils and
airway hyperresponsiveness are not causally related. Nevertheless, the clinical beneficial
effect of anti-IgE treatment has been demonstrated in large phase 3 trials, involving both
pediatric and adult patients with moderate to severe asthma (15-17). Based on these
data, anti-IgE has recently been approved by the Food and Drug Administration in the
US for patients with moderate to severe persistent, IgE-mediated asthma that is sub-
optimally controlled with inhaled steroids. Furthermore, we have shown that in patients
with mild persistent asthma treatment with anti-IgE for 12 weeks significantly improves
morning and evening PEF and reduces early and late allergen response (Chapter 7).
Thus, the question remains whether drugs have to reduce airway hyperresponsiveness in
order to be beneficial for asthma treatment. Therefore, the issue arises which outcome
parameters should prevail in proof of concept studies: the cellular and pathological
outcome, or the functional endpoints?
What is the implication of the persistent airway hyperresponsiveness under anti-IgE
treatment? IgE+ cells in the bronchial mucosa are significantly reduced following anti-
IgE treatment (Chapter 7). Apparently, airway hyperresponsiveness in patients with
asthma is independent of IgE. The clinical consequences of airway hyperresponsiveness
are reflected in an increased variation in airway caliber both within and between days
(PEF variability) (18). Indeed, PEF variability in our study did not change either.
However, this may be explained by the low level of PEF variability in our patient group
(Chapter 7). In patients with more severe asthma an effect of anti-IgE on PEF variability
has not been published.
The pathological mechanisms responsible for airway hyperreponsiveness may be related
to the altered behaviour of airway smooth muscle (10). Changes in the organization of
contractile filaments or in the plasticity of smooth muscle may underlie the persistence
of airway hyperresponsiveness (20). It could be argued that inhaled steroids are not only
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anti-inflammatory, but also change the functional properties of airway smooth muscle,
whereas anti-IgE treatment does not (21). Remarkably, it has recently been suggested in
a pilot study, that anti-TNF treatment reduces airway hyperresponsiveness and increases
FEV1, but does not affect inflammation (22). This may suggest that inflammation per se,
is not the right target for asthma therapy. Nevertheless, inflammation in the airway wall
may enhance airway narrowing during smooth muscle contraction and thereby lead to
airway hyperresponsiveness (23). Interestingly, the number of mast cells in the smooth
muscle of patients with asthma is inversely correlated with the PC20 methacholine in the
subjects with asthma (24). Following anti-IgE, the number of mast cells in the lamina
propria was not decreased (Chapter 7). Although, we have not analyzed the number of
mast cells in the airway smooth muscle, this might provide an explanation for the
unchanged airway hyperresponsiveness following anti-IgE treatment. 
Monitoring inflammation: there is more than eosinophils
The current GINA guidelines recommend that lung function and symptoms are
measured in order to adjust (anti-inflammatory) treatment and thereby maintain asthma
control (1). It is an interesting hypothesis that more direct monitoring airway
inflammation will lead to improved asthma control. Markers for monitoring airway
inflammation were investigated in this thesis in three different ways. First, inhaled
steroids improved airway hyperresponsiveness, sputum eosinophils and exhaled nitric
oxide; however these changes were not interrelated. Therefore, these markers may
provide complementary information when monitoring anti-inflammatory treatment in
asthma (Chapter 3). Second, anti-exudative effect of treatments can be determined via
the assessment of microvascular leakage in induced sputum following inhalation of
substance P (Chapter 4). Third, CD8 cells in bronchial biopsies predicted lung function
decline and thus demonstrated the prognostic value of inflammation in asthma (Chapter
5). Therefore, inflammation in asthma does not only consist of eosinophilic
inflammation.
Which criteria can be identified to determine the usefulness of markers for monitoring
inflammation in asthma? First, it is important to distinguish between markers for short-
and long-term outcome of asthma. At this moment most research is focused on the short-
term outcome of the disease. However, the inflammatory process within the airway may
have different effects on short- and long-term outcome of the disease. Indeed,
eosinophils have been shown to predict asthma exacerbations in a study with a follow-up
period of 8 weeks (25). On the other hand, we could not observe the prognostic value of
eosinophils in our follow-up study of 71⁄2 years (Chapter 5). Therefore, the prognostic
value of inflammatory markers may be different for short- and long-term follow-up.
Markers for short-term outcome of asthma have to be safe, non-invasive, reproducible,
accurate and easy to perform, since they have to be measured more often in the same
patient. Furthermore, these markers should be responsive to the effects of (or to
changes in) treatment, exposure or avoidance to allergens. This means that they should
mirror changes in the degree of inflammation. Next, markers may be selected on their







of asthma. For example, the negative predictive value of airway hyperresponsiveness for
asthma is very high (26). The diagnostic accuracy appears to increase if sputum
eosinophils and levels of exhaled NO are used in comparison with conventional
approaches as recommended in the guidelines (27). Alternatively, a marker should be
able to reliably distinguish between different disease severities. Whether a marker meets
this criterion is often tested by investigating the correlations with other measures of
asthma severity (symptoms and lung function). However, the lack of such a correlation
could also imply that this marker is reflecting a different component of the disease. We
also failed to demonstrate a correlation between steroid-induced changes in airway
hyperresponsiveness, sputum eosinophils and levels of exhaled NO (Chapter 3). This
could imply that the first improvements induced by inhaled steroid for the different
markers are “out of phase”. On the other hand, it could mean that these three markers
represent different features of asthma.
Measuring airway hyperresponsiveness has demonstrated its usefulness in asthma
management (28). Although it is safe and non-invasive, it may not be easy to perform in
a non-specialized setting. Nevertheless, measures of airway hyperresponsiveness may
provide additional and useful information, which is probably not always picked-up by
other markers of inflammation (29). Sputum eosinophils have also been effectively used
to guide anti-inflammatory treatment (30). Again, specialized personnel time is needed
for the induction and processing of sputum. Therefore, cost-effectiveness analyses are
needed to investigate the repetitive use of these markers in regular patient care, outside
a research setting. In Chapter 4, we have demonstrated that induced sputum can be used
to assess microvascular leakage. Neurogenic inflammation, which may result in
microvascular leakage, is an important component of the pathology in asthma (31).
Monitoring this feature of the inflammatory process might also lead to better asthma
control and should, therefore, be further explored. Improved asthma management
based on monitoring the levels of exhaled NO has been used in adults and children
(32;33). The measurement of exhaled NO is safe and non-invasive, but in contrast with
AHR and sputum eosinophils, it is easy to perform. However, the equipment needed to
measure exhaled NO is still very expensive. In the future, the measurement of exhaled
NO might be used in regular patient care. On the other hand, it may be questioned
whether these asthma management studies are sufficient proof that exhaled NO is a
appropriate marker for adjusting treatment. Indeed, the levels of exhaled NO appeared
not to predict loss of asthma control (25). Interestingly, the same study showed that
changes in sputum eosinophils were prognostic for loss of control (25). The study by
Leuppi and co-authors confirmed that both AHR and sputum eosinophils, but not
exhaled NO, are predictive for asthma exacerbations (34).
Assessing airway inflammation for markers of long-term outcome is important for
investigating the underlying mechanisms of the disease and for following the progression
and resolution of the disease. Consequently, the criteria “non-invasive” and “easy to
perform” may be less important, since these measures will not be performed frequently.
The prognostic significance of airway inflammation for the long-term outcome of asthma
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is still unclear. The lack of scientific evidence is probably due to the long duration
needed to investigate markers for longitudinal follow-up. To overcome this problem,
several cross-sectional studies have been performed. These cross-sectional studies have
shown associations between eosinophils and persistent airflow limitation (35;36).
Furthermore, others have demonstrated that the thickness of the sub-epithelial reticular
layer was inversely associated with the level of lung function in asthma (37;38). Still, it is
not known whether these cross-sectional associations hold after long-term follow-up.
Indeed, we have found that the cross-sectional associations with eosinophils and sub-
epithelial reticular layer thickness are not established in a longitudinal follow-up study
(Chapter 5). It is not unexpected that cross-sectional and follow-up studies have different
results, since cross-sectional studies do not include changes over time. Thus, longitudinal
follow-up studies are required to examine the usefulness of markers for monitoring
inflammation of long-term asthma outcome.
Management: how to distinguish asthma severity from asthma control?
Asthma is a heterogeneous disease. Patients who participate in clinical trials have to be
classified according to the severity of their disease for enrolment. Traditionally, asthma
severity is defined by the clinical features that are present in the absence of therapy. This
approach has also been used in the current GINA guidelines (Table 5-6) (1). Under
appropriate treatment these clinical features should be absent, otherwise there is lack of
control. To be able to identify patients who are at increased risk for exacerbation, there
is a growing need for a distinction between asthma severity and asthma control (39-41).
What is asthma severity? Asthma severity is meant to grade the underlying disease state.
In the current asthma guidelines, classification of asthma severity is assessed by the
clinical features that are present before treatment (1). These clinical features would
include symptoms and lung function. However, these clinical features are modified by
therapy. Therefore, treatment level should be taken into account relating asthma severity
to clinical symptoms (39). Asthma severity may vary from time to time in a single patient,
however, changes in asthma severity occur only relatively slowly over time.
What is asthma control? Asthma control, on the contrary, is meant to grade the current
expression of the disease as a result of treatment intervention. It is based on the goals of
optimal treatment as described in the asthma guidelines. These goals include the
absence of symptoms. On the other hand, minimal symptoms are allowed if they do not
(or only minimally) require rescue medication. Furthermore, lung function should be
normal or at least near the patient’s best. Asthma control will also mean control of
exacerbations. However, when defining disease control, inflammation should also be
taken in to account. Moreover, chronic control of asthma would indicate the prevention
of loss of lung function. 
Control can be achieved by patient education, environmental control and adequate
treatment. There are several reasons why patients with asthma may have poorly-
controlled disease. The most important reason is failure to adhere to treatment







reported (42). Second, untreated non-asthmatic conditions (gastroesophageal reflux,
rhino sinusitis, psychopathology co-morbidity) associated with asthma may lead to poor
asthma control. Finally, very severe asthma could also lead to uncontrolled asthma, but
only if the two reasons mentioned above are excluded (39). 
Although measures to assess control and severity of asthma overlap, there should be
emphasis on the distinction between asthma control and asthma severity. The common
perception that well-controlled asthma is synonymous with mild asthma and that poorly-
controlled asthma is synonymous with severe asthma is wrong. Asthma severity should be
defined by the minimum medication required to achieve asthma control (39). PEF
variability may be a measure that can be used to assess and improve asthma control.
Indeed, we have shown that PEF variability provides information in addition to symptoms
and ß2-agonist use and may therefore be valuable to adjust therapy in order to prevent
loss of asthma control (Chapter 6). The current GINA guidelines use PEF variability only
for the initial assessment before treatment. For the ongoing assessment of asthma
control during treatment, PEF variability is not included in the guidelines (1). Asthma
management studies using airway hyperresponsiveness (28), sputum eosinophils (30) or
exhaled NO (33) as a marker to adjust treatment have demonstrated that the current
guidelines are not optimal and can be improved. In addition, a treatment algorithm,
which includes the reduction of PEF variability, might also improve the asthma
management guidelines. Furthermore, the use of a composite measure to determine
asthma control has been proposed (43;44). In the current GINA guidelines the presence
of one of the features of a severity step is sufficient to place a patient in that category (1).
Finally, it has been suggested that the patient perception should be taken into account
(45). This would imply the inclusion of patient-centred outcomes in the asthma
management guidelines.
Directions for future research
The studies described in this thesis have gained more insight into airway inflammation in
patients with asthma. Despite the growing knowledge about the concept, monitoring and
management of asthma, many issues remain to be explored. Interesting questions for
futures studies may include:
● Which parameters should prevail in proof-of-concept studies?
● What is the clinical implication of the persistent airway hyperresponsiveness under
anti-IgE treatment?
● Can measurement of microvascular leakage be used to monitor airway inflammation
and thereby improve asthma control?
● Is it effective to adjust asthma treatment based on the levels of PEF- variability?
● What is the cost-effectiveness of non-invasive markers of airway inflammation to
monitor asthma treatment?
● Which markers are useful for monitoring inflammation of long-term asthma outcome?
● Is it possible to improve the current GINA guidelines by including non-invasive
markers of airway inflammation or by using a composite outcome?
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Patiënten met astma hebben het regelmatig benauwd. Kenmerkend voor de ziekte is dat
de benauwdheid gepaard gaat met een piepende ademhaling, hoesten en het opgeven
van slijm. Tussen de aanvallen van benauwdheid zijn patiënten doorgaans klachten vrij.
Meestal ontstaan de klachten op jonge leeftijd en is astma een chronische ziekte waarvan
patiënten gedurende hun hele leven last hebben. Het is echter ook mogelijk dat de
eerste symptomen pas op latere leeftijd optreden. Allergieën en astma gaan vaak samen.
Het merendeel van de patiënten is allergisch voor huisstofmijt, katten, honden, gras-
en/of boompollen. Tot op heden is de ziekte nog niet te genezen; een goede
behandeling is echter wel vaak mogelijk. Desondanks is het hebben van de ziekte astma
voor veel patiënten een grote beperking in het dagelijks leven.
Het percentage van de bevolking dat astma heeft, verschilt van land tot land. Van een
paar procent tot 1/3 van de mensen heeft symptomen. Bij 2 tot 12% van de personen is
ook de diagnose astma gesteld. Voor Nederland betekent dit dat er ongeveer 430.000
mensen astma hebben. Dit maakt astma wereldwijd tot een van de meest voorkomende
chronische ziekten. In de laatste decennia is het vóórkomen van astma flink
toegenomen. In enkele landen zijn de percentages sinds de jaren 70 zelfs verdubbeld. Er
is geen duidelijke verklaring voor deze stijging. Recente onderzoeken tonen echter aan
dat het aantal mensen met astma momenteel gelijk blijft of zelfs afneemt. Het zal in de
komende jaren duidelijk worden of deze trend doorzet.
Risicofactoren voor het krijgen van astma 
Astma is deels een erfelijke ziekte. Dit betekent dat wanneer de moeder of de vader
astma heeft, er een grote kans is dat hun kinderen de ziekte ook zullen krijgen. Het lijkt
er echter niet op dat één duidelijke genetische afwijking hiervoor verantwoordelijk is.
Zoals eerder aangegeven gaan allergieën en astma vaak samen. Allergisch zijn is dan ook
de belangrijkste risicofactor voor het ontwikkelen van de ziekte. Ook is aangetoond dat
een frequente blootstelling aan allergenen (huisstofmijt of dieren) in de omgeving, de
kans op het ontstaan van astma vergroot. Daarnaast lijkt het erop dat het doormaken van
bepaalde virusinfecties op jonge leeftijd het vervolgens krijgen van de ziekte
waarschijnlijker maakt. Kinderen die opgroeien op een boerderij daarentegen blijken
juist minder vaak allergieën en astma te hebben. Het bovenstaande suggereert dat het
voorkomen van astma mogelijk zou moeten zijn. Onderzoeken die gedaan zijn op het
gebied van preventie laten tot op heden teleurstellende resultaten zien. Zo bleek
bijvoorbeeld het verminderen van de blootstelling aan huisstofmijt bij pasgeborenen niet
te leiden tot minder astma. De meest overtuigende resultaten werden vooralsnog
gevonden bij onderzoek naar het effect van probiotica. Het gebruik van deze probiotica
(gezonde bacteriën) door zwangere vrouwen resulteerde namelijk in minder eczeem bij
hun kinderen. Misschien biedt dit een mogelijkheid om in de toekomst de ontwikkeling
van astma te voorkomen.
Luchtwegontsteking en astma
Het afweersysteem van patiënten met astma reageert uitzonderlijk op prikkels zoals
bijvoorbeeld katten. Hierdoor ontstaat de chronische ontsteking van de luchtwegen die
kenmerkend is voor astma. De slijmvliezen aan de binnenkant van de luchtwegen
zwellen op en produceren meer slijm dan normaal. Ook trekken de spieren om de
luchtwegen samen, waardoor de luchtwegen zich vernauwen. Dit geeft benauwdheid,
hoesten en/of een piepende ademhaling. Diverse stoffen en cellen komen vanuit de
bloedbaan de luchtwegen binnen en veroorzaken daar een ontstekingsreactie. Deze
ontsteking begint direct na het inademen van allergenen en gaat ook nog langer door
zodat de ontstekingsreactie chronisch wordt. Daarnaast leidt dit tot permanente
veranderingen in de structuur en samenstelling van het longweefsel. Hierdoor is de
longfunctie bij sommige patiënten blijvend verminderd.
Dit proefschrift
Dit proefschrift gaat over de luchtwegontsteking bij patiënten met astma. Hierbij is op
drie verschillende manieren naar deze ontsteking gekeken.
● ontstekingsmediatoren bij astma (dit zijn stoffen die het lichaam zelf aanmaakt tijdens
de ontstekingsreactie)
● het monitoren van luchtwegontsteking
● het behandelen van luchtwegontsteking
Rol van ontstekingsmediatoren
Achtergrond
IL-5 is een ontstekingsmediator die bij astma een belangrijke rol lijkt te spelen. Deze stof
wordt door het lichaam zelf gemaakt. Bij gezonde personen is IL-5 niet of nauwelijks
aanwezig, echter in patiënten met astma kan deze stof zowel in het bloed als in de
longen aangetoond worden. Hoe ernstiger de ziekte, des te meer IL-5 er door het
lichaam geproduceerd wordt. In het laboratorium en bij proefdieren is aangetoond dat
IL-5 in actieve rol speelt tijdens de ontstekingsreactie. IL-5 blijkt namelijk de eosinofiel
(een ontstekingscel) te laten rijpen en te activeren. Geactiveerde eosinofielen gaan dan
vanuit de bloedbaan naar de longen. Hier veroorzaken zij de ontstekingsreactie, die
vervolgens de voor astma zo bekende klachten van benauwdheid geeft. Het is echter nog
onduidelijk of IL-5 ook de gevoeligheid van de luchtwegen voor prikkels verhoogt. 
In hoofdstuk 2 gaat het over de volgende vragen:
Onderzoeksvragen
● Verhoogt IL-5 de gevoeligheid van de luchtwegen voor prikkels?
● Is het effect dat IL-5 heeft op de ziekte afhankelijk van de plaats (bloedbaan of








Patiënten met een lichte vorm van astma kregen IL-5 op 2 manieren toegediend: via
inademing zodat de stof direct in de longen komt en via een prik zodat het direct in de
bloedbaan komt. Vervolgens werden de hoeveelheid eosinofielen in het bloed en in de
longen gemeten. Ook werd de gevoeligheid van de luchtwegen voor prikkels bepaald.
Resultaten
IL-5 in de bloedbaan bleek direct de hoeveelheid eosinofielen in het bloed te doen
toenemen. IL-5 had echter geen effect op het aantal eosinofielen in de luchtwegen.
Interessant was dat de gevoeligheid van de luchtwegen voor prikkels niet veranderde
door de toediening van IL-5.
Conclusies
Het effect dat IL-5 heeft op de ontstekingsreactie bij patiënten met astma richt zich met
name op de bloedbaan. Omdat IL-5 geen invloed blijkt te hebben op de gevoeligheid
van de luchtwegen, speelt IL-5 waarschijnlijk geen cruciale rol bij astma. Een nieuw
geneesmiddel dat de werking van IL-5 blokkeert, bleek inderdaad bij patiënten met
astma niet effectief te zijn.
Monitoren van luchtwegontsteking
Achtergrond
De behandeling van astma is erop gericht om de luchtwegontsteking zoveel mogelijk te
verminderen. Hierbij is het van belang dat een arts precies weet hoe ernstig deze
ontsteking bij een patiënt is. Immers, ernstige luchtwegontsteking zou zware aanvallen
van benauwdheid en ook blijvende schade aan de luchtwegen kunnen veroorzaken.
Maar aan de andere kant leidt te veel medicatie ook tot onnodige bijwerkingen. De ernst
van de ontsteking varieert van patiënt tot patiënt, maar ook bij een patiënt kan de
luchtwegontsteking het ene moment ernstiger zijn dan op het andere. Het vragen naar
de hoeveelheid klachten zou een betrekkelijk eenvoudige manier kunnen zijn om de
ernst vast te stellen. Helaas blijken deze klachten geen goede weerspiegeling te zijn van
de ernst van de ontsteking. Dit komt mogelijk omdat patiënten klachten niet altijd goed
herkennen. Het kan ook veroorzaakt worden doordat klachten en ontsteking niet altijd
hand in hand gaan.
Er zijn drie verschillen methoden ontwikkeld waarmee luchtwegontsteking op een voor
de patiënt niet belastende manier gemeten kan worden.
Ten eerste het bepalen van de luchtwegovergevoeligheid voor de stof methacholine. Het
inademen van methacholine geeft bij gezonde personen geen klachten. Patiënten met
astma worden echter benauwd zodra zij methacholine inademen. Patiënten met ernstige
luchtwegontsteking blijken al van een lage hoeveelheid methacholine benauwd te
worden, terwijl patiënten met nauwelijks ontsteking pas na een hoge concentratie
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methacholine klachten krijgen. In het laboratorium kan op een veilige en
gecontroleerde manier de gevoeligheid van de luchtwegen voor methacholine bepaald
worden.
Het bepalen van de hoeveelheid eosinofielen (ontstekingscellen) in het slijm is de
tweede methode om luchtwegontsteking te bepalen. Een probleem hierbij is dat niet alle
patiënten dit slijm spontaan kunnen ophoesten. Echter na het inademen van een zoute
nevel lukt dit vaak wel. Vervolgens kan in dit opgehoeste slijm het aantal eosinofielen
bepaald worden. Hiermee wordt de mate van luchtwegontsteking vastgesteld.
Tot slot komt er in de uitgeademde lucht een stof voor die geproduceerd wordt tijdens
de ontstekingsreactie. Deze stof heet stikstof mono-oxide, afgekort NO. Door te blazen
in een apparaat (als bij een alcohol blaastest) wordt de hoeveelheid NO in de
uitgeademde lucht gemeten.
In hoofdstuk 3 van dit proefschrift zijn deze drie methoden met elkaar vergeleken.
Hierbij is gebruik gemaakt van een standaard onderhoudsmedicatie voor astma: inhalatie
cortico-steroïden. Van deze medicatie is bekend dat het de ontstekingsreactie remt.
Onderzoeksvraag
● Welk effect heeft een handeling met inhalatie cortico-steroïden op gevoeligheid van
de luchtwegen voor methacholine, op het aantal eosinofielen in het slijm en op de
hoeveelheid NO in de uitgeademde lucht bij patiënten met astma?
Onderzoeksmethoden
Vijfentwintig patiënten met astma zijn gedurende 4 weken behandeld met inhalatie
cortico-steroïden of placebo (een nepmiddel). Voor, tijdens en na deze behandeling zijn
gevoeligheid van de luchtwegen voor methacholine, het aantal eosinofielen in het slijm
en de hoeveelheid NO in de uitgeademde lucht bepaald.
Resultaten
De behandeling met inhalatie cortico-steroïden verminderde significant de gevoeligheid
van de luchtwegen voor methacholine, het aantal eosinofielen in het slijm en de
hoeveelheid NO in de uitgeademde lucht. Bij de patiënten die de placebo behandeling
hadden gekregen, werden geen veranderingen gemeten. Echter de door inhalatie
cortico-steroïden veroorzaakte afnames waren niet vergelijkbaar tussen de drie
methoden. De ene patiënt kon bijvoorbeeld een grote daling in het aantal eosinofielen
hebben en een kleine afname in NO, terwijl dit bij een andere patiënt juist weer het
omgekeerde was.
Conclusies
Alle drie de methoden zijn goed bruikbaar om de ernst van de luchtwegontsteking vast
te stellen. Ze geven echter wel verschillende informatie over deze ontsteking en moeten








Luchtwegontsteking bij astma bestaat niet alleen uit ontstekingscellen en mediatoren.
Het ontstaan van oedeem (zwelling door vocht) vormt ook een belangrijk onderdeel van
het ontstekingsproces. Het is echter niet goed mogelijk om de ernst van het oedeem bij
patiënten te meten. Het is bekend dat bij oedeemvorming, als gevolg van lekkage van de
bloedvaten, eiwitten in de luchtwegen komen. Deze eiwitten kunnen gemeten worden in
het opgehoeste slijm. 
In hoofdstuk 4 is onderzocht of opgehoest slijm geschikt is voor het monitoren van de
ernst van oedeem. Hierbij is gebruikt gemaakt van substance P. Substance P wordt
geproduceerd tijdens de ontstekingsreactie door de zenuwen in de luchtwegen. Het is
een van de belangrijkste veroorzakers van oedeem en lekkage. Het inademen van
substance P veroorzaakt benauwdheid bij patiënten. Als controle is gebruikt gemaakt van
neurokinine A. Deze stof is erg vergelijkbaar met substance P. Het wordt ook door de
zenuwen geproduceerd en geeft tevens benauwdheid. Neurokinine A veroorzaakt aan de
andere kant geen oedeem en lekkage.
Onderzoeksvraag
● Is het mogelijk om in opgehoest slijm de ernst van oedeem te bepalen?
Onderzoeksmethoden
Zowel voor als na het inademen van substance P werden patiënten met astma gevraagd
slijm op te hoesten. In dit slijm werden verschillende eiwitten die vrijkomen bij
oedeemvorming gemeten. Tevens werden dezelfde eiwitten bepaald voor en na het
inademen van neurokinine A.
Resultaten
Na inademing van substance P werden significant meer eiwitten gemeten dan na
neurokinine A. Dit verschil was het duidelijkst meetbaar bij het eiwit alpha-2-
macroglobuline.
Conclusies
Door middel van het inademen van substance P en het vervolgens ophoesten van slijm is
het goed mogelijk om de ernst van oedeem te bepalen. Hiermee kan in de toekomst
bijvoorbeeld ook het effect van nieuwe medicatie op oedeemvorming bepaald worden. 
Achtergrond
Bij een bepaalde groep astmapatiënten blijkt de longfunctie na verloop van tijd blijvend
af te nemen. Op dit moment is het nog niet mogelijk om te voorspellen bij welke
patiënten dit het geval zal zijn. Het lijkt erop dat luchtwegontsteking hierin een
belangrijke rol speelt. 
In hoofdstuk 5 is onderzocht of aan de hand van de ontsteking in de luchtwegen




● Voorspelt luchtwegontsteking de blijvende vermindering in longfunctie?
Onderzoeksmethoden
Bij 32 patiënten met astma was, in een ander onderzoek 71⁄2 jaar geleden, de ontsteking
in de luchtwegen bepaald. Deze bepaling was gedaan in een biopt dat in de luchtwegen
was genomen door middel van een bronchoscopie. Hierbij gaat de longarts met een
slangetje via de keel naar de longen en neemt daar minuscule hapjes (biopten). In deze
biopten kan bepaald worden welke ontstekingscellen er in de luchtwegen aanwezig zijn.
In het huidige onderzoek is bij dezelfde mensen opnieuw de longfunctie bepaald.
Vervolgens is berekend of en zo ja hoeveel, deze longfunctie was verminderd ten
opzichte van 71⁄2 jaar geleden. Tot slot is de relatie tussen de vermindering in longfunctie
en de ernst van de ontsteking bepaald.
Resultaten
De verschillen tussen de patiënten waren erg groot. In de afgelopen 71⁄2 jaar was bij
sommige patiënten de longfunctie verbeterd, terwijl bij anderen de longfunctie met
ruim 1 liter was afgenomen. Patiënten met een grote vermindering in longfunctie
bleken meer CD8 cellen te hebben, dan patiënten bij wie de longfunctie hetzelfde was
gebleven. Deze CD8 cel is een bekende ontstekingscel in de luchtwegen. De cel herkent
virussen en allergenen die ingeademd worden. Nadat de cel geactiveerd is, worden
andere ontstekingscellen aangetrokken en ook actief. Hierdoor ontstaat een
ontstekingsproces waarbij ook structurele veranderingen in de luchtwegen zouden
kunnen optreden. 
Conclusies
Luchtwegontsteking, en specifiek de hoeveelheid CD8 cellen, voorspelt de vermindering
in longfunctie bij patiënten met astma. Dit suggereert dat medicatie die gericht is tegen




Een arts zal bij de behandeling van astma er naar streven dat een patiënt zo min
mogelijk symptomen heeft. De belangrijkste medicijnen hiervoor zijn
ontstekingsremmers en luchtwegverwijders. Ontstekingsremmers bestrijden de
ontsteking in de luchtwegen. Luchtwegverwijders zorgen ervoor dat de spiertjes rondom
de luchtwegen verslappen, waardoor de luchtwegen bijna direct weer wijder worden en
de benauwdheid verdwijnt. Ontstekingsremmers moet een patiënt dagelijks innemen,
terwijl luchtwegverwijders alleen ingenomen hoeven te worden bij klachten van
benauwdheid om deze snel te verminderen. Daarnaast is het van belang dat de







ook thuis op een klein apparaat. Dit apparaat meet de maximale hoeveelheid
uitgeademde lucht, de zogenaamde PEF. Door de PEF dagelijks ’s ochtends en ’s avonds
te meten krijgt de arts een goed beeld van de longfunctie van een patiënt. Dus de
hoeveelheid ontstekingsremmers die een arts voorschrijft, is afhankelijk van de
symptomen, hoe vaak een patiënt luchtwegverwijders gebruikt en de longfunctie.
Als er een groot verschil is tussen de PEF die ’s ochtends en ’s avonds gemeten wordt,
kan dit wijzen op een instabiele fase van de ziekte. Een maat om dit aan te geven, is de
PEF variabiliteit. Deze PEF variabiliteit wordt op dit moment niet meegenomen in de
behandeling van astma. 
In hoofdstuk 6 is onderzocht of behandeling op basis van de PEF variabiliteit zinvol is.
Onderzoeksvraag
● Voorspelt de mate van PEF variabiliteit of de behandeling van astma onder controle is?
Onderzoeksmethoden
Bij 75 patiënten met astma, die volgens de huidige richtlijnen behandeld werden, werd
de PEF variabiliteit bepaald. Drie maanden later werd gekeken of bij deze patiënten het
astma onder controle was.
Resultaten
De patiënten bij wie de PEF variabiliteit in het begin van het onderzoek hoog was,
hadden 8 keer zoveel kans dat hun astma drie maanden later niet meer onder controle
was.
Conclusies
De mate van PEF variabiliteit voorspelt of astma onder controle is. Deze maat dient
daarom meegenomen te worden in de behandeling van astma. 
Achtergrond
Recent is er een nieuw medicijn voor astma ontwikkeld: omalizumab. Dit medicijn is een
antilichaam tegen IgE. Het stofje IgE wordt in het lichaam van allergische patiënten veel
geproduceerd en staat aan de basis van het ontstekingsproces. Omalizumab bindt aan
het IgE en zou op deze manier ontsteking verminderen, waardoor de allergie en
daarmee astmaklachten zouden afnemen. 
In hoofdstuk 7 is onderzocht welk effect omalizumab heeft op de ernst van astma.
Onderzoeksvragen
● Remt omalizumab de benauwdheid na het inademen van allergenen?
● Voorkomt omalizumab ontsteking na het inademen van allergenen?
● Verbetert omalizumab de PEF?
● Verlaagt omalizumab de gevoeligheid van de luchtwegen voor methacholine?
● Vermindert omalizumab het aantal eosinofielen in het slijm?
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Onderzoeksmethoden
Gedurende 12 weken zijn 25 astmapatiënten behandeld met omalizumab of placebo.
Voor en na deze behandeling is de benauwdheid na het inademen van allergenen
gemeten en is vervolgens met behulp van een bronchoscopie in een biopt de ontsteking
bepaald. Daarnaast hebben de patiënten dagelijks hun longfunctie door middel van de
PEF gemeten. Ook werd de gevoeligheid van de luchtwegen voor methacholine
vastgesteld en het aantal eosinofielen in het slijm bepaald.
Resultaten
Na 12 weken was de PEF verbeterd in de patiënten die met omalizumab behandeld
waren. Daarnaast bleek het inademen van allergenen geen benauwdheid of
luchtwegontsteking meer te geven. Ook was het aantal eosinofielen in het slijm sterk
verminderd. De gevoeligheid voor methacholine echter was onveranderd gebleven.
Conclusies
Omalizumab blijkt zowel luchtwegontsteking als klachten te doen afnemen bij patiënten
met astma. Het feit dat omalizumab de gevoeligheid voor methacholine niet vermindert,
dient verder onderzocht te worden.
Conclusies
De belangrijkste conclusies die getrokken kunnen worden, staan hieronder vermeld:
● Het effect dat IL-5 heeft op de ontstekingsreactie bij patiënten met astma richt zich
met name op de bloedbaan (hoofdstuk 2).
● De gevoeligheid van de luchtwegen voor methacholine, het aantal eosinofielen in
slijm en de hoeveelheid NO in de uitgeademde lucht zijn 3 methoden die goed
bruikbaar zijn om de ernst van de luchtwegontsteking vast te stellen (hoofdstuk3).
● Door middel van het inademen van substance P en het vervolgens ophoesten van slijm
is het goed mogelijk om de ernst van oedeem te bepalen (hoofdstuk 4).
● Luchtwegontsteking, en specifiek de hoeveelheid CD8 cellen, voorspelt de
vermindering in longfunctie bij patiënten met astma (hoofdstuk 5).
● De mate van PEF variabiliteit voorspelt of astma onder controle is (hoofdstuk 6).
● Omalizumab blijkt zowel luchtwegontsteking als klachten te doen afnemen bij








Dit proefschrift levert naast resultaten en conclusies, ook een aantal vragen op.
Hieronder staan de belangrijkste:
● Welke methode om luchtwegontsteking te monitoren is het meest kosten-effectief?
● Is het mogelijk om de behandeling van astma te verbeteren als de ernst van
luchtwegoedeem wordt meegenomen?
● Welke meting voorspelt de ernst van astma op de lange termijn?
● Is het mogelijk om astma beter onder controle te krijgen als de mate van PEF
variabiliteit bepaald wordt?
● Is het op den duur ongunstig voor de patiënt dat de verhoogde gevoeligheid van de
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